[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_4b38e3ff-8332-4d10-821d-a774627c4ab7":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:4b38e3ff-8332-4d10-821d-a774627c4ab7,\"}":70},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":27,"indexDatabases":35,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"4b38e3ff-8332-4d10-821d-a774627c4ab7","2023-12-05T07:18:40.470+00:00","2025-11-21T09:48:25.190+00:00",[],"International-Journal-of-Pharmaceutics",{"issn":12,"title":14},{"VOID":13},"03785173",{"EN":15},"International Journal of Pharmaceutics","PUBLISHER","PENDING",null,0,[21],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":23,"label":24,"description":26,"parentId":18,"standard":18,"scholarHubFieldId":18},"988aad6e-c496-4836-b969-f61991a0eed2",[],{"EN":25},"Pharmaceutical Science",{},[28],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":30,"slug":18,"properties":31,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":34,"statistic":18},"c749757b-dddf-4e6f-9697-b9c441adc06c",[],{"title":32},{"EN":33},"Elsevier",[],[36,53],{"id":37,"indexDatabase":38,"url":48,"indexYears":49,"academicFieldIds":50,"indexDatabaseRanking":52},"8959a074-8c8b-4bdc-93ec-0a2fc88870c2",{"id":39,"createTime":18,"updateTime":18,"relativeEntities":40,"label":41,"description":43,"key":45,"publicationTags":46,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":42,"VI":42},"Scopus - Elsevier",{"EN":42,"VI":44},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[47],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F22454","1978-2025",[51],"6e740848-171b-4f21-8d03-9fed10ed0384","SCOPUS__Q1",{"id":54,"indexDatabase":55,"url":67,"indexYears":18,"academicFieldIds":68,"indexDatabaseRanking":18},"c4c3796f-a4a7-4efb-b4c6-2bdc16c636d5",{"id":56,"createTime":18,"updateTime":18,"relativeEntities":57,"label":58,"description":60,"key":63,"publicationTags":64,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":59,"VI":59},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":61,"VI":62},"SCIE database","Cơ sở dữ liệu SCIE","scie",[65,66],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0378-5173",[69],"2b943d65-24a8-4546-9232-a1e32c12cb6c",{"meta":71,"data":73},{"total":72},"11063",[74,224,676,843,938,1240,1371,1498,1589,1771],{"id":75,"createTime":76,"updateTime":77,"relativeEntities":78,"slug":79,"properties":80,"entityType":88,"verifyStatus":89,"verifyTime":90,"verifyNote":91,"languages":18,"translateLanguages":92,"viewCount":19,"primaryUrl":94,"fullTextUrl":18,"authors":95,"publicationType":182,"publisherRelationship":183,"citationCount":18,"citationInfo":18,"publishDate":220,"publishYear":221,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":222,"openAccess":18,"references":18,"isForceReanalyzing":223},"104c7dd7-51fc-4033-a8fc-24e571b9ab1e","2024-01-14T09:35:26.361+00:00","2026-09-09T11:12:05.801+00:00",[],"Systemic-delivery-of-small-interfering-RNA-targeting-nuclear-factor-%CE%BAB-in-mice-with-collagen-induced-arthritis-using-arginine-histidine-cysteine-based-oligopeptide-modified-polymer-nanomicelles",{"title":81,"references":84,"doi":86},{"EN":82,"VI":83},"Systemic delivery of small interfering RNA targeting nuclear factor κB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles","Phân phối toàn thân RNA can thiệp nhỏ nhắm đích yếu tố nhân κB ở chuột nhắt viêm khớp do collagen bằng các nanomicelle polymer biến tính oligopeptide trên cơ sở arginine-histidine-cysteine",{"VOID":85},"Agarwal, 2011, Biologic agents in rheumatoid arthritis: an update for managed care professionals, J. Manag. Care Pharm., 17, S14, 10.18553\u002Fjmcp.2011.17.s9-b.S14\nBrown, 2008, The roles of the classical and alternative nuclear factorkappaB pathways: potential implications for autoimmunity and rheumatoid arthritis, Arthritis Res. Ther., 10, 212, 10.1186\u002Far2457\nBuch, 2007, Longterm infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders, Rheumatology (Oxford), 46, 1153, 10.1093\u002Frheumatology\u002Fkem075\nCriswell, 2010, Gene discovery in rheumatoid arthritis highlights the CD40\u002FNF-(B signaling pathway in disease pathogenesis, Immunol. Rev., 233, 55, 10.1111\u002Fj.0105-2896.2009.00862.x\nDadouna, 2013, Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis, Joint Bone Spine, 80, 29, 10.1016\u002Fj.jbspin.2012.02.005\nFeist, 2013, Small molecules targeting JAKs–a new approach in the treatment of rheumatoid arthritis, Rheumatology (Oxford), 52, 1352, 10.1093\u002Frheumatology\u002Fkes417\nGabriel, 2001, The epidemiology of rheumatoid arthritis, Rheum. Dis. Clin. North Am., 27, 269, 10.1016\u002FS0889-857X(05)70201-5\nHofkens, 2011, Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis, Int. J. Pharm., 416, 486, 10.1016\u002Fj.ijpharm.2011.02.060\nKanazawa, 2011, Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration, Pharm. Res., 28, 2130, 10.1007\u002Fs11095-011-0440-7\nKanazawa, 2013, Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles, Biomaterials, 34, 9220, 10.1016\u002Fj.biomaterials.2013.08.036\nKanazawa, 2015, Topical anti-nuclear factor-kappa B small interfering RNA with functional peptides containing sericin-based hydrogel for atopic dermatitis, Pharmaceutics, 7, 294, 10.3390\u002Fpharmaceutics7030294\nKanazawa, 2015, Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis, Int. J. Pharm., 489, 261, 10.1016\u002Fj.ijpharm.2015.05.003\nLee, 2003, Pharmacological treatment of established rheumatoid arthritis, Best Pract. Res. Clin. Rheumatol., 17, 811, 10.1016\u002FS1521-6942(03)00048-2\nMcInnes, 2011, The pathogenesis of rheumatoid arthritis, N. Engl. J. Med., 365, 2205, 10.1056\u002FNEJMra1004965\nMetselaar, 2004, Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis, Ann. Rheum. Dis., 63, 348, 10.1136\u002Fard.2003.009944\nOkada, 2014, Cytoplasm-responsive delivery systems for siRNA using cell-penetrating peptide nanomicelles, J. Drug Delivery Sci. Technol., 24, 3, 10.1016\u002FS1773-2247(14)50001-9\nPasparakis, 2009, Regulation of tissue homeostasis by NF-(B signalling: implications for inflammatory diseases, Nat. Rev. Immunol., 9, 778, 10.1038\u002Fnri2655\nPincus, 1998, Aggressive treatment of early rheumatoid arthritis to prevent joint damage, Bull. Rheumatol. Dis., 47, 2\nShinde, 2014, Methotrexate: a gold standard for treatment of rheumatoid arthritis, J. Pain Palliat. Care Pharmacother., 28, 351, 10.3109\u002F15360288.2014.959238\nSimmonds, 2008, Signalling, inflammation and arthritis: NF-(B and its relevance to arthritis and inflammation, Rheumatology (Oxford), 47, 584, 10.1093\u002Frheumatology\u002Fkem298\nSmolen, 2007, New therapies for the treatment of rheumatoid arthritis, Lancet, 370, 1861, 10.1016\u002FS0140-6736(07)60784-3\nSzekanecz, 2013, New insights in synovial angiogenesis, Joint Bone Spine, 77, 13, 10.1016\u002Fj.jbspin.2009.05.011\nTanaka, 2010, Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhances siRNA uptake and gene silencing, Int. J. Pharm., 398, 219, 10.1016\u002Fj.ijpharm.2010.07.038\nTanaka, 2013, Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery, Int. J. Pharm., 455, 40, 10.1016\u002Fj.ijpharm.2013.07.069\nTrotta, 2004, Deformable liposomes for dermal administration of methotrexate, Int. J. Pharm., 270, 119, 10.1016\u002Fj.ijpharm.2003.10.006\nUchida, 2011, Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002, J. Pharmacol. Exp. Ther., 338, 443, 10.1124\u002Fjpet.111.180042\nZhou, 2014, Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis, J. Clin. Invest., 124, 4363, 10.1172\u002FJCI75673\nvan Loo, 2011, Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis, Arthritis Res. Ther., 13, 221, 10.1186\u002Far3324\nvan den Hoven, 2011, Liposomal drug formulations in the treatment of rheumatoid arthritis, Mol. Pharm., 8, 1002, 10.1021\u002Fmp2000742",{"VOID":87},"10.1016\u002Fj.ijpharm.2016.10.033","PUBLICATION","VERIFIED","2025-02-06T16:38:01.059+00:00","Auto Verify",[93],"VI","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517316309760",[96,112,126,140,154,168],{"id":97,"sortIndex":19,"researcher":18,"roles":98,"affiliations":100,"properties":109,"displayName":111,"givenName":18,"familyName":18},"0c926a02-0e2d-46b1-81db-a74d1ddc341d",[99],"AUTHOR",[101],{"id":102,"sortIndex":19,"affiliation":103,"properties":18},"827dfe69-1edf-4d31-83ac-b0862933e193",{"id":102,"createTime":18,"updateTime":18,"relativeEntities":104,"slug":18,"properties":105,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":108,"statistic":18},[],{"title":106},{"VI":107},"School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392 Japan",[],{"title":110},{"VI":111},"Takanori Kanazawa",{"id":113,"sortIndex":114,"researcher":18,"roles":115,"affiliations":116,"properties":123,"displayName":125,"givenName":18,"familyName":18},"290ec05d-53e6-49fb-be25-62a90006c4b7",1,[99],[117],{"id":102,"sortIndex":19,"affiliation":118,"properties":18},{"id":102,"createTime":18,"updateTime":18,"relativeEntities":119,"slug":18,"properties":120,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":122,"statistic":18},[],{"title":121},{"VI":107},[],{"title":124},{"VI":125},"Takahiro Endo",{"id":127,"sortIndex":128,"researcher":18,"roles":129,"affiliations":130,"properties":137,"displayName":139,"givenName":18,"familyName":18},"0ab55f31-02de-45be-9760-d441d7d26ab8",2,[99],[131],{"id":102,"sortIndex":19,"affiliation":132,"properties":18},{"id":102,"createTime":18,"updateTime":18,"relativeEntities":133,"slug":18,"properties":134,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":136,"statistic":18},[],{"title":135},{"VI":107},[],{"title":138},{"VI":139},"Naoki Arima",{"id":141,"sortIndex":142,"researcher":18,"roles":143,"affiliations":144,"properties":151,"displayName":153,"givenName":18,"familyName":18},"fcf5d66f-f8d8-4287-8815-66a185ab7ecf",3,[99],[145],{"id":102,"sortIndex":19,"affiliation":146,"properties":18},{"id":102,"createTime":18,"updateTime":18,"relativeEntities":147,"slug":18,"properties":148,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":150,"statistic":18},[],{"title":149},{"VI":107},[],{"title":152},{"VI":153},"Hisako Ibaraki",{"id":155,"sortIndex":156,"researcher":18,"roles":157,"affiliations":158,"properties":165,"displayName":167,"givenName":18,"familyName":18},"ac9ad8ee-c34f-4b25-9fb3-d2ff52d1ac9c",4,[99],[159],{"id":102,"sortIndex":19,"affiliation":160,"properties":18},{"id":102,"createTime":18,"updateTime":18,"relativeEntities":161,"slug":18,"properties":162,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":164,"statistic":18},[],{"title":163},{"VI":107},[],{"title":166},{"VI":167},"Yuuki Takashima",{"id":169,"sortIndex":170,"researcher":18,"roles":171,"affiliations":172,"properties":179,"displayName":181,"givenName":18,"familyName":18},"12437e6b-a475-418f-99ff-28146f523a1a",5,[99],[173],{"id":102,"sortIndex":19,"affiliation":174,"properties":18},{"id":102,"createTime":18,"updateTime":18,"relativeEntities":175,"slug":18,"properties":176,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":178,"statistic":18},[],{"title":177},{"VI":107},[],{"title":180},{"VI":181},"Yasuo Seta","ARTICLE",{"url":94,"publisher":184,"properties":215},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":185,"slug":10,"properties":186,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":189,"manageAffiliations":194,"indexDatabases":200,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":187,"title":188},{"VOID":13},{"EN":15},[190],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":191,"label":192,"description":193,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[195],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":196,"slug":18,"properties":197,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":199,"statistic":18},[],{"title":198},{"EN":33},[],[201,208],{"id":37,"indexDatabase":202,"url":48,"indexYears":49,"academicFieldIds":207,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":203,"label":204,"description":205,"key":45,"publicationTags":206,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":209,"url":67,"indexYears":18,"academicFieldIds":214,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":210,"label":211,"description":212,"key":63,"publicationTags":213,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":216,"volume":218},{"VOID":217},"315-323",{"VOID":219},"515","2016-12-01",2016,[65,52],false,{"id":225,"createTime":226,"updateTime":227,"relativeEntities":228,"slug":229,"properties":230,"entityType":88,"verifyStatus":89,"verifyTime":237,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":238,"fullTextUrl":18,"authors":239,"publicationType":182,"publisherRelationship":309,"citationCount":346,"citationInfo":347,"publishDate":352,"publishYear":221,"citationAnalyzeStatus":353,"lastCitationAnalyze":227,"indexDatabases":354,"openAccess":18,"references":355,"isForceReanalyzing":223},"de2b5921-daa1-4905-8019-2d48263de590","2023-12-07T04:23:35.206+00:00","2026-08-24T19:41:12.801+00:00",[],"Development-and-characterisation-of-sustained-release-solid-dispersion-oral-tablets-containing-the-poorly-water-soluble-drug-disulfiram",{"title":231,"gsPaper":233,"doi":235},{"EN":232},"Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram",{"VOID":234},"[\"7153134164590504081\"]",{"VOID":236},"10.1016\u002Fj.ijpharm.2015.11.029","2024-04-27T07:42:32.344+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517315303744",[240,255,268,281,294],{"id":241,"sortIndex":19,"researcher":18,"roles":242,"affiliations":243,"properties":252,"displayName":254,"givenName":18,"familyName":18},"47953b25-d9cd-461a-9108-168af0956567",[99],[244],{"id":245,"sortIndex":19,"affiliation":246,"properties":18},"fea97ae6-09fb-4690-b4aa-33e0b3d70078",{"id":245,"createTime":18,"updateTime":18,"relativeEntities":247,"slug":18,"properties":248,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":251,"statistic":18},[],{"title":249},{"VI":250},"School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wulfrana Street, Wolverhampton WV1 1LY, UK",[],{"title":253},{"VI":254},"Mandip Shergill",{"id":256,"sortIndex":114,"researcher":18,"roles":257,"affiliations":258,"properties":265,"displayName":267,"givenName":18,"familyName":18},"ae15af73-3ef9-4300-a356-109da9c59b73",[99],[259],{"id":245,"sortIndex":19,"affiliation":260,"properties":18},{"id":245,"createTime":18,"updateTime":18,"relativeEntities":261,"slug":18,"properties":262,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":264,"statistic":18},[],{"title":263},{"VI":250},[],{"title":266},{"VI":267},"Mina Patel",{"id":269,"sortIndex":128,"researcher":18,"roles":270,"affiliations":271,"properties":278,"displayName":280,"givenName":18,"familyName":18},"eba15c8e-cf4d-414c-bd46-1ea10cd715d8",[99],[272],{"id":245,"sortIndex":19,"affiliation":273,"properties":18},{"id":245,"createTime":18,"updateTime":18,"relativeEntities":274,"slug":18,"properties":275,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":277,"statistic":18},[],{"title":276},{"VI":250},[],{"title":279},{"VI":280},"Siraj Khan",{"id":282,"sortIndex":142,"researcher":18,"roles":283,"affiliations":284,"properties":291,"displayName":293,"givenName":18,"familyName":18},"991e30de-3384-4662-afc0-27ca22c80322",[99],[285],{"id":245,"sortIndex":19,"affiliation":286,"properties":18},{"id":245,"createTime":18,"updateTime":18,"relativeEntities":287,"slug":18,"properties":288,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":290,"statistic":18},[],{"title":289},{"VI":250},[],{"title":292},{"VI":293},"Ayesha Bashir",{"id":295,"sortIndex":156,"researcher":18,"roles":296,"affiliations":297,"properties":306,"displayName":308,"givenName":18,"familyName":18},"b22ae2ea-1b4c-4571-a602-0f6f74481b1a",[99],[298],{"id":299,"sortIndex":19,"affiliation":300,"properties":18},"bf5b007a-4592-43df-8c4c-a2a516e0c9fc",{"id":299,"createTime":18,"updateTime":18,"relativeEntities":301,"slug":18,"properties":302,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":305,"statistic":18},[],{"title":303},{"VI":304},"School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK",[],{"title":307},{"VI":308},"Christopher McConville",{"url":238,"publisher":310,"properties":341},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":311,"slug":10,"properties":312,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":315,"manageAffiliations":320,"indexDatabases":326,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":313,"title":314},{"VOID":13},{"EN":15},[316],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":317,"label":318,"description":319,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[321],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":322,"slug":18,"properties":323,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":325,"statistic":18},[],{"title":324},{"EN":33},[],[327,334],{"id":37,"indexDatabase":328,"url":48,"indexYears":49,"academicFieldIds":333,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":329,"label":330,"description":331,"key":45,"publicationTags":332,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":335,"url":67,"indexYears":18,"academicFieldIds":340,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":336,"label":337,"description":338,"key":63,"publicationTags":339,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":342,"volume":344},{"VOID":343},"3-11",{"VOID":345},"497",55,{"total":346,"publishYear":221,"statisticByYear":348},{"2016":114,"2017":349,"2018":170,"2019":170,"2020":349,"2021":349,"2022":350,"2024":351,"2025":128,"2026":128},9,7,6,"2016-01-01","ERROR_IN_ANALYZE_CITATION",[65,52],[356,364,370,378,386,389,392,400,403,411,419,425,431,439,445,451,459,465,471,476,482,490,498,506,515,518,526,529,537,545,549,555,563,571,579,586,594,602,610,613,616,619,627,632,640,643,646,652,660,668,671],{"id":18,"text":357,"url":358,"identifiers":359},"Abdul-Fattah, 2002, Preparation and in vitro evaluation of solid dispersions of halofantrine, Int. J. Pharm., 235, 17, 10.1016\u002FS0378-5173(01)00941-3","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0378-5173(01)00941-3",{"mag":360,"openalex":361,"pm":362,"doi":363},"2110692350","W2110692350","11879736","10.1016\u002Fs0378-5173(01)00941-3",{"id":365,"text":366,"url":367,"identifiers":368},"4c68646b-0035-4279-8000-0006b275d4fa","Agarwal, 2007, Rapid degradation of disulfiram by serum albumin, Res. Commun. Chem. Pathol. Pharmacol., 42, 293","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10440-022-00541-7",{"doi":369},"10.1007\u002Fs10440-022-00541-7",{"id":18,"text":371,"url":372,"identifiers":373},"Brar, 2004, Disulfiram inhibits activating transcription factor\u002Fcyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease, Mol. Cancer Ther., 3, 1049, 10.1158\u002F1535-7163.1049.3.9","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1535-7163.1049.3.9",{"mag":374,"openalex":375,"pm":376,"doi":377},"1911235202","W1911235202","15367699","10.1158\u002F1535-7163.1049.3.9",{"id":18,"text":379,"url":380,"identifiers":381},"Brewster, 2007, Cyclodextrins as pharmaceutical solubilizers, Adv. Drug. Deliv. Rev., 59, 645, 10.1016\u002Fj.addr.2007.05.012","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.addr.2007.05.012",{"mag":382,"openalex":383,"pm":384,"doi":385},"2074582913","W2074582913","17601630","10.1016\u002Fj.addr.2007.05.012",{"id":365,"text":387,"url":367,"identifiers":388},"Carr, 1965, Evaluating flow properties of solids, Chem. Eng., 72, 163",{"doi":369},{"id":365,"text":390,"url":367,"identifiers":391},"Cen, 2002, Disulfiram induces apoptosis in human melanoma cells: a redox-related process, Mol. Cancer Ther., 1, 197",{"doi":369},{"id":18,"text":393,"url":394,"identifiers":395},"Cen, 2004, Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells, J. Med. Chem., 47, 6914, 10.1021\u002Fjm049568z","https:\u002F\u002Fdoi.org\u002F10.1021\u002Fjm049568z",{"mag":396,"openalex":397,"pm":398,"doi":399},"2061460308","W2061460308","15615540","10.1021\u002Fjm049568z",{"id":18,"text":401,"url":18,"identifiers":402},"Chaudhari, 2006, Current trends in solid dispersions techniques, Pharm. Rev., 4, 2",{},{"id":18,"text":404,"url":405,"identifiers":406},"Chauhan, 2005, Preparation and evaluation of glibenclamide polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique, Eur. J. Pharm. Sci., 26, 219, 10.1016\u002Fj.ejps.2005.06.005","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejps.2005.06.005",{"mag":407,"openalex":408,"pm":409,"doi":410},"1998580244","W1998580244","16087324","10.1016\u002Fj.ejps.2005.06.005",{"id":18,"text":412,"url":413,"identifiers":414},"Chen, 2006, Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity, Cancer Res., 66, 10425, 10.1158\u002F0008-5472.CAN-06-2126","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-06-2126",{"mag":415,"openalex":416,"pm":417,"doi":418},"2036180531","W2036180531","17079463","10.1158\u002F0008-5472.can-06-2126",{"id":420,"text":421,"url":422,"identifiers":423},"d3844af0-0bb2-4263-a27c-d165a3380e48","Cho, 2014, Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet, Eur. J. Pharm. Sci., 11, 1, 10.1016\u002Fj.ejps.2013.12.016","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0928098713004880",{"doi":424},"10.1016\u002Fj.ejps.2013.12.016",{"id":426,"text":427,"url":428,"identifiers":429},"cc292255-f23e-470d-80f8-3cdbaa939c57","Claxton, 2001, A systematic review of the associations between dose regimens and medication compliance, Clin. Ther., 23, 1296, 10.1016\u002FS0149-2918(01)80109-0","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0149291801801090",{"doi":430},"10.1016\u002Fs0149-2918(01)80109-0",{"id":18,"text":432,"url":433,"identifiers":434},"Dufour, 1993, Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study, Biotherapy, 6, 9, 10.1007\u002FBF01877380","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fbf01877380",{"mag":435,"openalex":436,"pm":437,"doi":438},"2023965930","W2023965930","8389572","10.1007\u002Fbf01877380",{"id":440,"text":441,"url":442,"identifiers":443},"8aa3d7d6-018f-45a3-9aba-e01e72de6fbd","Fleisher, 1996, Improved oral drug delivery: solubility limitations overcome by the use of prodrugs, Adv. Drug. Deliv. Rev., 19, 115, 10.1016\u002F0169-409X(95)00103-E","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0169409X9500103E",{"doi":444},"10.1016\u002F0169-409x(95)00103-e",{"id":446,"text":447,"url":448,"identifiers":449},"6cff923f-953c-4990-acbc-7b34ff1a6830","Gupta, 2004, Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective, Pharm. Res., 21, 1762, 10.1023\u002FB:PHAM.0000045226.42859.b8","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1023\u002FB:PHAM.0000045226.42859.b8",{"doi":450},"10.1023\u002FB:PHAM.0000045226.42859.b8",{"id":18,"text":452,"url":453,"identifiers":454},"Gupte, 2009, Elevated copper and oxidative stress in cancer cells as a target for cancer treatment, Cancer Treat. Rev., 35, 32, 10.1016\u002Fj.ctrv.2008.07.004","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ctrv.2008.07.004",{"mag":455,"openalex":456,"pm":457,"doi":458},"2157567077","W2157567077","18774652","10.1016\u002Fj.ctrv.2008.07.004",{"id":460,"text":461,"url":462,"identifiers":463},"806057e1-fa6f-4481-93a2-915cb628151e","Hancock, 1997, Characteristics and significance of the amorphous state in pharmaceutical systems, J. Pharm. Sci., 86, 1, 10.1021\u002Fjs9601896","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS002235491550227X",{"doi":464},"10.1021\u002Fjs9601896",{"id":466,"text":467,"url":468,"identifiers":469},"087c61e9-1ee0-44c2-bff5-8b525e875ff2","Hintzen, 2014, In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin, Int. J. Pharm., 29, 20, 10.1016\u002Fj.ijpharm.2014.05.047","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517314003949",{"doi":470},"10.1016\u002Fj.ijpharm.2014.05.047",{"id":18,"text":472,"url":473,"identifiers":474},"Hülsmann, 2000, Melt extrusion: an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrates, Eur. J. Pharm. Biopharm., 49, 237, 10.1016\u002FS0939-6411(00)00077-1","http:\u002F\u002Fdx.doi.org\u002F10.1016\u002Fs0939-6411(00)00077-1",{"doi":475},"10.1016\u002Fs0939-6411(00)00077-1",{"id":18,"text":477,"url":478,"identifiers":479},"Janssens, 2009, Review: physical chemistry of solid dispersions, J. Pharm. Pharmacol., 61, 1571, 10.1211\u002Fjpp.61.12.0001","https:\u002F\u002Fdoi.org\u002F10.1211\u002Fjpp.61.12.0001",{"openalex":480,"doi":481},"W4210982805","10.1211\u002Fjpp.61.12.0001",{"id":18,"text":483,"url":484,"identifiers":485},"Johansson, 1992, A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites, Acta. Psychiatr. Scand. Suppl., 369, 15, 10.1111\u002Fj.1600-0447.1992.tb03310.x","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1600-0447.1992.tb03310.x",{"mag":486,"openalex":487,"pm":488,"doi":489},"2084541153","W2084541153","1471547","10.1111\u002Fj.1600-0447.1992.tb03310.x",{"id":18,"text":491,"url":492,"identifiers":493},"Karavas, 2006, Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone, Eur. J. Pharm. Biopharm., 63, 103, 10.1016\u002Fj.ejpb.2006.01.016","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejpb.2006.01.016",{"mag":494,"openalex":495,"pm":496,"doi":497},"2071060910","W2071060910","16675209","10.1016\u002Fj.ejpb.2006.01.016",{"id":18,"text":499,"url":500,"identifiers":501},"Keen, 2013, Investigation of process temperature and screw speed on properties of a pharmaceutical solid dispersion using corotating and counter-rotating twin-screw extruders, J. Pharm. Pharmacol., 66, 204, 10.1111\u002Fjphp.12106","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjphp.12106",{"mag":502,"openalex":503,"pm":504,"doi":505},"2151744035","W2151744035","24433423","10.1111\u002Fjphp.12106",{"id":18,"text":507,"url":508,"identifiers":509},"Ketola, 2012, Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells, PLoS One, 7, e51470, 10.1371\u002Fjournal.pone.0051470","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0051470",{"mag":510,"pmc":511,"openalex":512,"pm":513,"doi":514},"2110395715","3520796","W2110395715","23251544","10.1371\u002Fjournal.pone.0051470",{"id":365,"text":516,"url":367,"identifiers":517},"Krishnaiah, 2010, Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs, J. Bioequivalence Availability, 2, 28",{"doi":369},{"id":18,"text":519,"url":520,"identifiers":521},"Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016\u002FS0939-6411(00)00076-X","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0939-6411(00)00076-x",{"mag":522,"openalex":523,"pm":524,"doi":525},"2044594845","W2044594845","10840192","10.1016\u002Fs0939-6411(00)00076-x",{"id":365,"text":527,"url":367,"identifiers":528},"Liu, 2012, Cytotoxic effect of disulfiram\u002Fcopper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells, Br. J. Cancer, 107, 1488, 10.1038\u002Fbjc.2012.442",{"doi":369},{"id":18,"text":530,"url":531,"identifiers":532},"Lljin, 2009, High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth, Clin. Cancer Res., 15, 6070, 10.1158\u002F1078-0432.CCR-09-1035","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1078-0432.ccr-09-1035",{"mag":533,"openalex":534,"pm":535,"doi":536},"2156873394","W2156873394","19789329","10.1158\u002F1078-0432.ccr-09-1035",{"id":18,"text":538,"url":539,"identifiers":540},"McConville, 2013, Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781, Eur. J. Pharm. Biopharm., 83, 322, 10.1016\u002Fj.ejpb.2012.10.007","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejpb.2012.10.007",{"mag":541,"openalex":542,"pm":543,"doi":544},"1976501785","W1976501785","23159711","10.1016\u002Fj.ejpb.2012.10.007",{"id":18,"text":546,"url":18,"identifiers":547},"Millard, 2002, Solubilization by cosolvents. Establishing useful constants for the log-linear model, Int. J. Pharm., 245, 153, 10.1016\u002FS0378-5173(02)00334-4",{"doi":548},"10.1016\u002FS0378-5173(02)00334-4",{"id":550,"text":551,"url":552,"identifiers":553},"7459f3f6-4e11-4aa2-b970-83424fb88e14","Miyako, 2010, Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect, Int. J. Pharm., 393, 48, 10.1016\u002Fj.ijpharm.2010.03.059","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517310002334",{"doi":554},"10.1016\u002Fj.ijpharm.2010.03.059",{"id":18,"text":556,"url":557,"identifiers":558},"Moschwitzer, 2012, Drug nanocrystals in the commercial pharmaceutical development process, Int. J. Pharm., 453, 142, 10.1016\u002Fj.ijpharm.2012.09.034","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijpharm.2012.09.034",{"mag":559,"openalex":560,"pm":561,"doi":562},"2054260281","W2054260281","23000841","10.1016\u002Fj.ijpharm.2012.09.034",{"id":18,"text":564,"url":565,"identifiers":566},"Muhrer, 2006, Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug–polymer solid dispersions, Int. J. Pharm., 308, 69, 10.1016\u002Fj.ijpharm.2005.10.026","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijpharm.2005.10.026",{"mag":567,"openalex":568,"pm":569,"doi":570},"2012911843","W2012911843","16324806","10.1016\u002Fj.ijpharm.2005.10.026",{"id":18,"text":572,"url":573,"identifiers":574},"Mukherjee, 2010, Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole, J. Pharm. Pharmacol., 62, 1112, 10.1111\u002Fj.2042-7158.2010.01149.x","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.2042-7158.2010.01149.x",{"mag":575,"openalex":576,"pm":577,"doi":578},"1868071150","W1868071150","20796189","10.1111\u002Fj.2042-7158.2010.01149.x",{"id":18,"text":580,"url":581,"identifiers":582},"Pokharkar, 2006, Development, characterization and stabilization of amorphous form of a low Tg drug, Powder Technol., 167, 20, 10.1016\u002Fj.powtec.2006.05.012","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.powtec.2006.05.012",{"mag":583,"openalex":584,"doi":585},"2000505705","W2000505705","10.1016\u002Fj.powtec.2006.05.012",{"id":18,"text":587,"url":588,"identifiers":589},"Pouton, 2006, Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur. J. Pharm. Sci., 29, 278, 10.1016\u002Fj.ejps.2006.04.016","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejps.2006.04.016",{"mag":590,"openalex":591,"pm":592,"doi":593},"2056995570","W2056995570","16815001","10.1016\u002Fj.ejps.2006.04.016",{"id":18,"text":595,"url":596,"identifiers":597},"Ramadhani, 2014, Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram, Int. J. Pharm, 475, 514, 10.1016\u002Fj.ijpharm.2014.09.013","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijpharm.2014.09.013",{"mag":598,"openalex":599,"pm":600,"doi":601},"2042801908","W2042801908","25218186","10.1016\u002Fj.ijpharm.2014.09.013",{"id":18,"text":603,"url":604,"identifiers":605},"Rambali, 2003, Itraconazole formulation studies of the melt-extrusion process with mixture design, Drug Dev. Ind. Pharm., 29, 641, 10.1081\u002FDDC-120021313","https:\u002F\u002Fdoi.org\u002F10.1081\u002Fddc-120021313",{"mag":606,"openalex":607,"pm":608,"doi":609},"2125835249","W2125835249","12889782","10.1081\u002Fddc-120021313",{"id":365,"text":611,"url":367,"identifiers":612},"Ratnaparkhi, 2013, Sustained release oral drug delivery system – an overview, IJPRR, 2, 11",{"doi":369},{"id":18,"text":614,"url":18,"identifiers":615},"Rios, 2006, Developments in powder flow testing, Pharm. Technol., 30, 38",{},{"id":365,"text":617,"url":367,"identifiers":618},"Savjani, 2012, Drug solubility: importance and enhancement techniques, ISRN Pharm., 2012, 195727",{"doi":369},{"id":18,"text":620,"url":621,"identifiers":622},"Serajuddin, 2007, Salt formation to improve drug solubility, Adv. Drug. Deliv. Rev., 59, 603, 10.1016\u002Fj.addr.2007.05.010","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.addr.2007.05.010",{"mag":623,"openalex":624,"pm":625,"doi":626},"2952528349","W2952528349","17619064","10.1016\u002Fj.addr.2007.05.010",{"id":18,"text":628,"url":629,"identifiers":630},"Sinha, 2010, Solid dispersion as an approach for bioavailability enhancemen of poorly water-soluble drug ritonavir, AAPS PharmSciTech, 11, 518, 10.1208\u002Fs12249-010-9404-1","http:\u002F\u002Fdx.doi.org\u002F10.1208\u002Fs12249-010-9404-1",{"doi":631},"10.1208\u002Fs12249-010-9404-1",{"id":18,"text":633,"url":634,"identifiers":635},"Tran, 2014, Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion, Int. J. Pharm., 450, 79, 10.1016\u002Fj.ijpharm.2013.04.022","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijpharm.2013.04.022",{"mag":636,"openalex":637,"pm":638,"doi":639},"2032518425","W2032518425","23612354","10.1016\u002Fj.ijpharm.2013.04.022",{"id":18,"text":641,"url":18,"identifiers":642},"United States Pharmacopeia National Formulary U.S.P. 32, 2009.",{},{"id":18,"text":644,"url":18,"identifiers":645},"United States Pharmacopeia, Chapter 1174, Powder flow.",{},{"id":647,"text":648,"url":649,"identifiers":650},"59d7b7cb-0289-4021-b1c0-1e880cabe0ce","Van den Mooter, 2006, Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs, Int. J. Pharm., 316, 1, 10.1016\u002Fj.ijpharm.2006.02.025","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517306001499",{"doi":651},"10.1016\u002Fj.ijpharm.2006.02.025",{"id":18,"text":653,"url":654,"identifiers":655},"Vasanthavada, 2004, Phase behavior of amorphous molecular dispersions I: determination of the degree and mechanism of solid solubility, Pharm. Res., 21, 1598, 10.1023\u002FB:PHAM.0000041454.76342.0e","https:\u002F\u002Fdoi.org\u002F10.1023\u002Fb:pham.0000041454.76342.0e",{"mag":656,"openalex":657,"pm":658,"doi":659},"1966423358","W1966423358","15497685","10.1023\u002Fb:pham.0000041454.76342.0e",{"id":18,"text":661,"url":662,"identifiers":663},"Verma, 1990, A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram, Am. J. Clin. Oncol., 13, 119, 10.1097\u002F00000421-199004000-00007","https:\u002F\u002Fdoi.org\u002F10.1097\u002F00000421-199004000-00007",{"mag":664,"openalex":665,"pm":666,"doi":667},"1977037705","W1977037705","2180271","10.1097\u002F00000421-199004000-00007",{"id":365,"text":669,"url":367,"identifiers":670},"Yellela, 2010, Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs, J. Bioequivalence Availability, 2, 28",{"doi":369},{"id":18,"text":672,"url":673,"identifiers":674},"Yip, 2011, Disulfiram modulated ROS-MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties, Br. J. Cancer, 104, 1564, 10.1038\u002Fbjc.2011.126","http:\u002F\u002Fdx.doi.org\u002F10.1038\u002Fbjc.2011.126",{"doi":675},"10.1038\u002Fbjc.2011.126",{"id":677,"createTime":678,"updateTime":679,"relativeEntities":680,"slug":681,"properties":682,"entityType":88,"verifyStatus":89,"verifyTime":689,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":690,"fullTextUrl":18,"authors":691,"publicationType":182,"publisherRelationship":761,"citationCount":142,"citationInfo":798,"publishDate":801,"publishYear":799,"citationAnalyzeStatus":353,"lastCitationAnalyze":802,"indexDatabases":803,"openAccess":18,"references":804,"isForceReanalyzing":223},"3c997726-f192-4340-801e-41e5eba2e828","2023-12-11T21:17:50.000+00:00","2026-08-19T09:06:55.958+00:00",[],"Potentiation-of-oxytetracycline-antimicrobial-activity-in-vivo-by-concurrent-administration-of-bromhexine",{"title":683,"gsPaper":685,"doi":687},{"EN":684},"Potentiation of oxytetracycline antimicrobial activity in vivo by concurrent administration of bromhexine",{"VOID":686},"3542960779810794538",{"VOID":688},"10.1016\u002F0378-5173(88)90061-0","2024-04-24T02:41:34.141+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0378517388900610",[692,707,720,733,748],{"id":693,"sortIndex":19,"researcher":18,"roles":694,"affiliations":695,"properties":704,"displayName":706,"givenName":18,"familyName":18},"5ee7f043-e4b1-4cf3-8d72-b0be6bf2c8eb",[99],[696],{"id":697,"sortIndex":19,"affiliation":698,"properties":18},"fe235f48-b34c-40c0-9f71-5a8b56c5d9ac",{"id":697,"createTime":18,"updateTime":18,"relativeEntities":699,"slug":18,"properties":700,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":703,"statistic":18},[],{"title":701},{"VI":702},"Pharmaceutical Sciences Research Group, Department of Pharmacy, Brighton Polytechnic, BrightonU.K.",[],{"title":705},{"VI":706},"Jaspal S. Malhi",{"id":708,"sortIndex":114,"researcher":18,"roles":709,"affiliations":710,"properties":717,"displayName":719,"givenName":18,"familyName":18},"d2ea437b-8e52-4078-9324-3e7274eea324",[99],[711],{"id":697,"sortIndex":19,"affiliation":712,"properties":18},{"id":697,"createTime":18,"updateTime":18,"relativeEntities":713,"slug":18,"properties":714,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":716,"statistic":18},[],{"title":715},{"VI":702},[],{"title":718},{"VI":719},"Anita-Jane High",{"id":721,"sortIndex":128,"researcher":18,"roles":722,"affiliations":723,"properties":730,"displayName":732,"givenName":18,"familyName":18},"3fb92fe5-2076-4200-8ad3-12ad232e925b",[99],[724],{"id":697,"sortIndex":19,"affiliation":725,"properties":18},{"id":697,"createTime":18,"updateTime":18,"relativeEntities":726,"slug":18,"properties":727,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":729,"statistic":18},[],{"title":728},{"VI":702},[],{"title":731},{"VI":732},"Geoffrey W. Hanlon",{"id":734,"sortIndex":142,"researcher":18,"roles":735,"affiliations":736,"properties":743,"displayName":745,"givenName":18,"familyName":18},"a1becc85-8315-4ee4-a8fb-2f3b3458bcc8",[99],[737],{"id":697,"sortIndex":19,"affiliation":738,"properties":18},{"id":697,"createTime":18,"updateTime":18,"relativeEntities":739,"slug":18,"properties":740,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":742,"statistic":18},[],{"title":741},{"VI":702},[],{"title":744,"gsAuthor":746},{"VI":745},"Paul R. Gard",{"VOID":747},"EQ-9GvIAAAAJ",{"id":749,"sortIndex":156,"researcher":18,"roles":750,"affiliations":751,"properties":758,"displayName":760,"givenName":18,"familyName":18},"bcab3f9e-6598-4fef-b5b9-58301c0dfa3a",[99],[752],{"id":697,"sortIndex":19,"affiliation":753,"properties":18},{"id":697,"createTime":18,"updateTime":18,"relativeEntities":754,"slug":18,"properties":755,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":757,"statistic":18},[],{"title":756},{"VI":702},[],{"title":759},{"VI":760},"Christopher Marriott",{"url":690,"publisher":762,"properties":793},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":763,"slug":10,"properties":764,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":767,"manageAffiliations":772,"indexDatabases":778,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":765,"title":766},{"VOID":13},{"EN":15},[768],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":769,"label":770,"description":771,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[773],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":774,"slug":18,"properties":775,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":777,"statistic":18},[],{"title":776},{"EN":33},[],[779,786],{"id":37,"indexDatabase":780,"url":48,"indexYears":49,"academicFieldIds":785,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":781,"label":782,"description":783,"key":45,"publicationTags":784,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":787,"url":67,"indexYears":18,"academicFieldIds":792,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":788,"label":789,"description":790,"key":63,"publicationTags":791,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":794,"volume":796},{"VOID":795},"77-81",{"VOID":797},"43",{"total":142,"publishYear":799,"statisticByYear":800},1988,{"1993":128,"1994":114},"1988-04-01","2026-08-19T09:06:55.957+00:00",[65,52],[805,808,811,814,817,820,824,827,831,839],{"id":18,"text":806,"url":18,"identifiers":807},"Abdou, 1975, Observations on the increase in the oxytetracycline level in the bronchial mucosa of pigs when using a simultaneous dosage with bromhexine, Tierarztl. Umschau, 30, 565",{},{"id":18,"text":809,"url":18,"identifiers":810},"Bach, 1972, The effect of bromhexine on the penetrance of oxytetracycline into sputum, S. Afr. Med. J., 46, 1512",{},{"id":18,"text":812,"url":18,"identifiers":813},"Brown, 1983, Antibiotic binding to purified mucus glycoproteins, J. Pharm. Pharmacol., 35, 80P",{},{"id":18,"text":815,"url":18,"identifiers":816},"Burgi, 1971, Changes in sputum fibre systems and viscosity during treatment with bromhexine, Clin. Trials J., 8, 37",{},{"id":18,"text":818,"url":18,"identifiers":819},"Cowan, 1974, Characters and characteristics, 42",{},{"id":18,"text":821,"url":18,"identifiers":822},"Kearney, 1987, The effects of mucus glycoprotein on the availability of tetracycline. II, Binding. Int. J. Pharm., 35, 211, 10.1016\u002F0378-5173(87)90132-3",{"doi":823},"10.1016\u002F0378-5173(87)90132-3",{"id":18,"text":825,"url":18,"identifiers":826},"Kotzian, 1976, Increase in oxytetracycline level in the bronchial mucus following simultaneous administration of Bisolvon, Tierarztl. Umschau, 32Jg, 132",{},{"id":18,"text":828,"url":18,"identifiers":829},"Malhi, 1986, The effect of oral mucolytic agents on the microflora of guinea pig uteri, J. Pharm. Pharmacol, 38, 38P, 10.1111\u002Fj.2042-7158.1986.tb14267.x",{"doi":830},"10.1111\u002Fj.2042-7158.1986.tb14267.x",{"id":18,"text":832,"url":833,"identifiers":834},"Marriott, 1975, The effect of tetracyclines on the viscoelastic properties of bronchial mucus, Biorheology, 12, 391, 10.3233\u002FBIR-1975-12610","https:\u002F\u002Fdoi.org\u002F10.3233\u002Fbir-1975-12610",{"mag":835,"openalex":836,"pm":837,"doi":838},"2407636721","W2407636721","2355","10.3233\u002Fbir-1975-12610",{"id":18,"text":840,"url":18,"identifiers":841},"Turner, 1985, The influence of native porcine gastric mucus gel on hydrogen ion diffusion, J. Pharm. Pharmacol, 37, 776, 10.1111\u002Fj.2042-7158.1985.tb04967.x",{"doi":842},"10.1111\u002Fj.2042-7158.1985.tb04967.x",{"id":844,"createTime":845,"updateTime":846,"relativeEntities":847,"slug":848,"properties":849,"entityType":88,"verifyStatus":89,"verifyTime":858,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":859,"fullTextUrl":18,"authors":860,"publicationType":182,"publisherRelationship":895,"citationCount":19,"citationInfo":932,"publishDate":935,"publishYear":933,"citationAnalyzeStatus":353,"lastCitationAnalyze":936,"indexDatabases":937,"openAccess":18,"references":18,"isForceReanalyzing":223},"e628b66b-a380-4ef0-80e0-48dbef03f4d8","2023-12-26T04:55:08.111+00:00","2026-08-19T09:06:55.927+00:00",[],"Self-assembled-%CE%B3-cyclodextrin-as-nanocarriers-for-enhanced-ocular-drug-bioavailability",{"title":850,"gsPaper":852,"references":854,"doi":856},{"EN":851},"Self-assembled γ-cyclodextrin as nanocarriers for enhanced ocular drug bioavailability",{"VOID":853},"[\"7797285217126144053\"]",{"VOID":855},"Abu Hashim, 2010, Potential use of γ-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin, Int. J. Pharm., 392, 83, 10.1016\u002Fj.ijpharm.2010.03.026\nAbuçafy, 2018, Supramolecular cyclodextrin-based metal-organic frameworks as efficient carrier for anti-inflammatory drugs, Eur. J. Pharm. Biopharm., 127, 112, 10.1016\u002Fj.ejpb.2018.02.009\nAigner, 2002, Investigation of tenoxicam and γ-cyclodextrin binary and ternary complexes, J. Incl. Phenom. Macrocycl. Chem., 42, 227, 10.1023\u002FA:1016011119666\nAnand, 2013, Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery, Photochem. Photobiol. Sci., 12, 1841, 10.1039\u002Fc3pp50169h\nArgenziano, 2017, Cyclodextrin-based nanohydrogels containing polyamidoamine units: A new dexamethasone delivery system for inflammatory diseases, Gels, 3, 22, 10.3390\u002Fgels3020022\nArima, 2006, Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes, J. Drug Target., 14, 225, 10.1080\u002F10611860600711136\nAvila-Salas, 2018, Rational development of a novel hydrogel as a pH-sensitive controlled release system for nifedipine, Polymers, 10, 806, 10.3390\u002Fpolym10070806\nBíró, 2019, Current approaches to use cyclodextrins and mucoadhesive polymers in ocular drug delivery—A mini-review, Sci. Pharm., 87, 15, 10.3390\u002Fscipharm87030015\nBrewster, 2007, Cyclodextrins as pharmaceutical solubilizers, Adv. Drug Deliv. Rev., 59, 645, 10.1016\u002Fj.addr.2007.05.012\nBucatariu, 2016, Poly(lactide-co-glycolide)\u002Fcyclodextrin (polyethyleneimine) microspheres for controlled delivery of dexamethasone, React. Funct. Polym., 107, 46, 10.1016\u002Fj.reactfunctpolym.2016.08.008\nCarlotti, 2007, Inclusion of cinnamaldehyde in modified γ-cyclodextrins, J. Incl. Phenom., 57, 445, 10.1007\u002Fs10847-006-9232-9\nChen, 2021, Novel γ-cyclodextrin-metal–organic frameworks for encapsulation of curcumin with improved loading capacity, physicochemical stability and controlled release properties, Food Chem., 347, 10.1016\u002Fj.foodchem.2020.128978\nCrini, 2014, Review: a history of cyclodextrins, Chem. Rev, 114, 10940, 10.1021\u002Fcr500081p\nDe Bie, 1998, Disposition of [14C]γ-cyclodextrin in germ-free and conventional rats, Regul. Toxicol. Pharmacol., 27, 150, 10.1006\u002Frtph.1998.1219\nDonaubauer, 1998, Subchronic intravenous toxicity studies with γ-cyclodextrin in rats, Regul. Toxicol. Pharmacol., 27, 189, 10.1006\u002Frtph.1998.1224\ndos Santos, 2010, Functionalization of acrylic hydrogels with α-, β- or γ-cyclodextrin modulates protein adsorption and antifungal delivery, Acta Biomater., 6, 3919, 10.1016\u002Fj.actbio.2010.04.013\nDuchêne, 2011, Cyclodextrins and their inclusion complexes, 1\nFábián, 2021, Carboxymethyl-γ-cyclodextrin, a novel selective relaxant binding agent for the reversal of neuromuscular block induced by aminosteroid neuromuscular blockers: an ex vivo laboratory study, BMC Anesthesiol., 21, 206, 10.1186\u002Fs12871-021-01424-4\nFernández, 2008, Analysis of the complexation of gemfibrozil with γ- and hydroxypropyl-γ-cyclodextrins, J. Pharm. Biomed. Anal., 47, 943, 10.1016\u002Fj.jpba.2008.02.029\nFrench, 1957, The Schardinger dextrins, Adv. Carbohydr. Chem., 12, 189\nFrömming, 1994\nGonzález-Gaitano, 2002, The aggregation of cyclodextrins as studied by photon correlation spectroscopy, J. Incl. Phenom., 44, 101, 10.1023\u002FA:1023065823358\nGonzález-Louzao, 2020, Encapsulation of finasteride with native and modified γ-cyclodextrins. Extensive characterization of the complexes, Int. J. Pharm., 587, 10.1016\u002Fj.ijpharm.2020.119619\nGoswami, 2018, Fluorescence, FTIR and 1H NMR studies of the inclusion complexes of the painkiller lornoxicam with β-, γ-cyclodextrins and their hydroxy propyl derivatives in aqueous solutions at different pHs and in the solid state, New J. Chem., 42, 15146, 10.1039\u002FC8NJ03093F\nGudmundsdottir, 2014, γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man, J. Ocul. Pharmacol. Ther., 30, 35, 10.1089\u002Fjop.2013.0060\nHagiwara, 2006, Prolonged retention of doxorubicin in tumor cells by encapsulation of γ-cyclodextrin complex in pegylated liposomes, J. Incl. Phenom. Macrocycl. Chem., 56, 65, 10.1007\u002Fs10847-006-9062-9\nHartlieb, 2017, Encapsulation of ibuprofen in CD-MOF and related bioavailability studies, Mol. Pharm., 14, 1831, 10.1021\u002Facs.molpharmaceut.7b00168\nHashidzume, 2017, Cyclodextrin, 269\nHigashi, 2010, Simultaneous dissolution of naproxen and flurbiprofen from a novel ternary gamma-cyclodextrin complex, Chem. Pharm. Bull. (Tokyo), 58, 769, 10.1248\u002Fcpb.58.769\nHigashi, 2007, Polypseudorotaxanes of pegylated insulin with cyclodextrins: Application to sustained release system, Bioorganic Med. Chem. Lett., 17, 1871, 10.1016\u002Fj.bmcl.2007.01.029\nHigashi, 2008, Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system, Biomaterials, 29, 3866, 10.1016\u002Fj.biomaterials.2008.06.019\nHigashi, 2009, Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: Slow release and resistance to enzymatic degradation, Chem. Pharm. Bull., 57, 541, 10.1248\u002Fcpb.57.541\nHigashi, 2019, One-pot synthesis of cyclodextrin-based radial poly[n]catenanes, Commun. Chem., 2, 78, 10.1038\u002Fs42004-019-0180-x\nHigashi, 2017, Stabilizing effects for antibody formulations and safety profiles of cyclodextrin polypseudorotaxane hydrogels, J. Pharm. Sci., 106, 1266, 10.1016\u002Fj.xphs.2017.01.002\nHigashi, 2012, Cyclodextrin\u002Fpoly(ethylene glycol) polypseudorotaxane hydrogels as a promising sustained-release system for lysozyme, J. Pharm. Sci., 101, 2891, 10.1002\u002Fjps.23232\nHigashi, 2015, Design and evaluation of the highly concentrated human IgG formulation using cyclodextrin polypseudorotaxane hydrogels, AAPS PharmSciTech, 16, 1290, 10.1208\u002Fs12249-015-0309-x\nIrie, 1982, Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro, J. Pharmacobiodyn., 5, 741, 10.1248\u002Fbpb1978.5.741\nJacob, 2018, Cyclodextrin complexes: Perspective from drug delivery and formulation, Drug Dev. Res., 79, 201, 10.1002\u002Fddr.21452\nJansook, 2021, Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery – A review, Int. J. Pharm., 606, 10.1016\u002Fj.ijpharm.2021.120955\nJansook, 2021, Effect of salt formation on γ-cyclodextrin solubilization of irbesartan and candesartan and the chemical stability of their ternary complexes, J. Drug Deliv Sci. Technol., 102980\nJansook, 2019, Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes, Carbohydr. Polym., 225, 10.1016\u002Fj.carbpol.2019.115209\nJansook, 2018, Cyclodextrin solubilization of celecoxib: solid and solution state characterization, J. Incl. Phenom. Macrocycl. Chem., 90, 75, 10.1007\u002Fs10847-017-0769-6\nJansook, 2010, Cyclodextrins as solubilizers: Formation of complex aggregates, J. Pharm. Sci., 99, 719, 10.1002\u002Fjps.21861\nJansook, 2008, γCD\u002FHPγCD: synergistic solubilization, Int. J. Pharm., 363, 217, 10.1016\u002Fj.ijpharm.2008.07.011\nJansook, 2009, CDs as solubilizers: effects of excipients and competing drugs, Int. J. Pharm., 379, 32, 10.1016\u002Fj.ijpharm.2009.06.005\nJansook, 2020, Development of amphotericin B nanosuspensions for fungal keratitis therapy: effect of self-assembled γ-cyclodextrin, J. Pharm. Investig., 50, 513, 10.1007\u002Fs40005-020-00474-z\nJansook, 2010, Effect of self-aggregation of γ-cyclodextrin on drug solubilization, J. Incl. Phenom. Macrocycl. Chem., 68, 229, 10.1007\u002Fs10847-010-9779-3\nJansook, 2015, Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan\u002FγCD eye drops, Pharm. Dev. Technol., 20, 626, 10.3109\u002F10837450.2014.910811\nJansook, 2018, Cyclodextrins: structure, physicochemical properties and pharmaceutical applications, Int. J. Pharm., 535, 272, 10.1016\u002Fj.ijpharm.2017.11.018\nJansook, 2016, Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B, Drug Dev. Ind. Pharm., 42, 1446, 10.3109\u002F03639045.2016.1141932\nJansook, 2020, Solubilization and in vitro permeation of dovitinib\u002Fcyclodextrin complexes and their aggregates, J. Incl. Phenom. Macrocycl. Chem., 97, 195, 10.1007\u002Fs10847-020-00995-y\nJansook, 2010, yCD\u002FHPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension, J. Pharm. Pharm. Sci., 13, 336, 10.18433\u002FJ3M88B\nJansook, 2010, Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension, Eur. J. Pharm. Biopharm., 76, 208, 10.1016\u002Fj.ejpb.2010.07.005\nJóhannesson, 2014, Dorzolamide cyclodextrin nanoparticle suspension eye drops and Trusopt in rabbit, J. Ocul. Pharmacol. Ther., 30, 464, 10.1089\u002Fjop.2013.0164\nJóhannesson, 2014, Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid, Acta Ophthalmol., 92, 550, 10.1111\u002Faos.12334\nJohannsdottir, 2018, Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo, J. Drug Deliv. Sci. Technol., 48, 125, 10.1016\u002Fj.jddst.2018.09.007\nJohannsdottir, 2018, Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits, J. Drug Deliv. Sci. Technol., 45, 449, 10.1016\u002Fj.jddst.2018.04.007\nJóhannsdóttir, 2015, Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations, Int. J. Pharm., 493, 86, 10.1016\u002Fj.ijpharm.2015.07.040\nJohannsdottir, 2017, Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles, Int. J. Pharm., 529, 486, 10.1016\u002Fj.ijpharm.2017.07.044\nJozwiakowski, 1985, Aqueous solubility behavior of three cyclodextrins, Carbohydr. Res., 143, 51, 10.1016\u002FS0008-6215(00)90694-3\nJug, 2020, Chapter two - Cyclodextrin-based drug delivery systems, 29\nKallab, 2021, Bio-distribution and pharmacokinetics of topically administered γ-cyclodextrin based eye drops in rabbits, Pharmaceuticals, 14, 480, 10.3390\u002Fph14050480\nKlang, 2012, Effect of γ-cyclodextrin on the in vitro skin permeation of a steroidal drug from nanoemulsions: Impact of experimental setup, Int. J. Pharm., 423, 535, 10.1016\u002Fj.ijpharm.2011.11.037\nKlang, 2011, Development of sucrose stearate-based nanoemulsions and optimisation through γ-cyclodextrin, Eur. J. Pharm. Biopharm., 79, 58, 10.1016\u002Fj.ejpb.2011.01.010\nKøhler, 2016, Hydration differences explain the large variations in the complexation thermodynamics of modified γ-cyclodextrins with bile salts, J. Phys. Chem. B., 120, 396, 10.1021\u002Facs.jpcb.5b10536\nKondo, 1990, In vitro action of human and porcine alpha-amylases on cyclomalto-oligosaccharides, Carbohydr. Res., 204, 207, 10.1016\u002F0008-6215(90)84036-T\nKonrádsdóttir, 2009, Drug targeting to the hair follicles: a cyclodextrin-based drug delivery, AAPS PharmSciTech, 10, 266, 10.1208\u002Fs12249-009-9205-6\nKoutsou, 1999, Gastrointestinal tolerance of gamma-cyclodextrin in humans, Food Addit. Contam., 16, 313, 10.1080\u002F026520399283984\nKristinsson, 1996, Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans, Invest. Ophthalmol. Vis. Sci., 37, 1199\nKritskiy, 2019, γ-Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide, Carbohydr. Polym., 216, 224, 10.1016\u002Fj.carbpol.2019.04.037\nKurkov, 2013, Cyclodextrins, Int. J. Pharm., 453, 167, 10.1016\u002Fj.ijpharm.2012.06.055\nLi, 2017, Cyclodextrin-based metal-organic frameworks particles as efficient carriers for lansoprazole: Study of morphology and chemical composition of individual particles, Int. J. Pharm., 531, 424, 10.1016\u002Fj.ijpharm.2017.05.056\nLi, 2007, γ-Cyclodextrin: a review on enzymatic production and applications, Appl. Microbiol. Biotechnol., 77, 245, 10.1007\u002Fs00253-007-1166-7\nLi, 2021, γ-Cyclodextrin metal–organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma. Drug Deliv, Transl. Res.\nLina, 1998, Subchronic oral toxicity studies with γ-cyclodextrin in rats, Regul. Toxicol. Pharmacol., 27, 178, 10.1006\u002Frtph.1998.1223\nLiu, 2002, The driving forces in the inclusion complexation of cyclodextrins, J. Incl. Phenom., 42, 1, 10.1023\u002FA:1014520830813\nLiu, 2017, Effect of guest drug character encapsulated in the cavity and intermolecular spaces of γ-cyclodextrins on the dissolution property of ternary γ-cyclodextrin complex, Int. J. Pharm., 531, 543, 10.1016\u002Fj.ijpharm.2017.04.049\nLoftsson, 2014, Self-assembled cyclodextrin nanoparticles and drug delivery, J. Incl. Phenom. Macrocycl. Chem., 80, 1, 10.1007\u002Fs10847-013-0375-1\nLoftsson, 2015, Excipient pharmacokinetics and profiling, Int. J. Pharm., 480, 48, 10.1016\u002Fj.ijpharm.2015.01.022\nLoftsson, 1996, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci., 85, 1017, 10.1021\u002Fjs950534b\nLoftsson, 2010, Pharmaceutical applications of cyclodextrins: basic science and product development, J. Pharm. Pharmacol., 62, 1607, 10.1111\u002Fj.2042-7158.2010.01030.x\nLoftsson, 2011, Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes, J. Pharm. Pharmacol., 63, 1119, 10.1111\u002Fj.2042-7158.2011.01279.x\nLoftsson, 2012, Cyclodextrins as functional excipients: Methods to enhance complexation efficiency, J. Pharm. Sci., 101, 3019, 10.1002\u002Fjps.23077\nLoftsson, 2007, Cyclodextrins and their pharmaceutical applications, Int. J. Pharm., 329, 1, 10.1016\u002Fj.ijpharm.2006.10.044\nLoftsson, 2005, Evaluation of cyclodextrin solubilization of drugs, Int. J. Pharm., 302, 18, 10.1016\u002Fj.ijpharm.2005.05.042\nLoftsson, 2003, The effects of organic salts on the cyclodextrin solubilization of drugs, Int. J. Pharm., 262, 101, 10.1016\u002FS0378-5173(03)00334-X\nLoftsson, 2007, Dexamethasone delivery to posterior segment of the eye, J. Incl. Phenom. Macrocycl. Chem., 57, 585, 10.1007\u002Fs10847-006-9253-4\nLoftsson, 2002, Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye, Acta Ophthalmol. Scand., 80, 144, 10.1034\u002Fj.1600-0420.2002.800205.x\nLoftsson, 2007, Cyclodextrins in ocular drug delivery: theoretical basis with dexamethasone as a sample drug, J. Drug Deliv. Sci. Technol., 17, 3, 10.1016\u002FS1773-2247(07)50001-8\nLoftsson, 2008, Carvedilol: Solubilization and cyclodextrin complexation: A technical note, AAPS PharmSciTech, 9, 425, 10.1208\u002Fs12249-008-9055-7\nLorenzo-Soler, 2021, Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure, Acta Ophthalmol., 99, 376, 10.1111\u002Faos.14639\nLorenzo-Veiga, 2020, In vitro and ex vivo evaluation of nepafenac-based cyclodextrin microparticles for treatment of eye inflammation, Nanomaterials (Basel), 10, 709, 10.3390\u002Fnano10040709\nLorenzo-Veiga, 2019, Nepafenac-loaded cyclodextrin\u002Fpolymer nanoaggregates: A new approach to eye drop formulation, Materials (Basel), 12, 229, 10.3390\u002Fma12020229\nMangelings, 2020, Chapter 9 - Recent developments in liquid and supercritical fluid chromatographic enantioseparations, 453, 10.1016\u002FB978-0-444-64070-3.00009-6\nMarican, 2018, Rational design, synthesis and evaluation of γ-CD-containing cross-linked polyvinyl alcohol hydrogel as a prednisone delivery platform, Pharmaceutics, 10, 30, 10.3390\u002Fpharmaceutics10010030\nMatsuda, 1983, Acute toxicity study of γ-cyclodextrin (γ-CD) in mice and rats, Pharmacometrics, 26, 287\nMennini, 2016, Development of cyclodextrin hydrogels for vaginal delivery of dehydroepiandrosterone, J. Pharm. Pharmacol., 68, 762, 10.1111\u002Fjphp.12549\nMessner, 2011, Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone\u002Fcyclodextrin complexes, Int. J. Pharm., 407, 174, 10.1016\u002Fj.ijpharm.2011.01.011\nMessner, 2010, Self-assembled cyclodextrin aggregates and nanoparticles, Int. J. Pharm., 387, 199, 10.1016\u002Fj.ijpharm.2009.11.035\nMiranda, 2011, Cyclodextrins and ternary complexes: Technology to improve solubility of poorly soluble drugs, Braz. J. Pharm. Sci., 47, 665, 10.1590\u002FS1984-82502011000400003\nMonnaert, 2004, Effects of γ- and hydroxypropyl-γ-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier, J. Pharmacol. Exp. Ther., 311, 1115, 10.1124\u002Fjpet.104.071845\nMotoyama, 2011, In vito gene delivery mediated by asialofetuin-appended cationic liposomes associated with γ-cyclodextrin into hepatocytes, J. Drug Deliv., 2011, 10.1155\u002F2011\u002F476137\nMoya-Ortega, 2012, Cyclodextrin-based nanogels for pharmaceutical and biomedical applications, Int. J. Pharm., 428, 152, 10.1016\u002Fj.ijpharm.2012.02.038\nMoya-Ortega, 2010, γ-Cyclodextrin hydrogels and semi-interpenetrating networks for sustained delivery of dexamethasone, Carbohydr. Polym., 80, 900, 10.1016\u002Fj.carbpol.2010.01.004\nMoya-Ortega, 2013, Dexamethasone eye drops containing γ-cyclodextrin-based nanogels, Int. J. Pharm., 441, 507, 10.1016\u002Fj.ijpharm.2012.11.002\nMuankaew, 2016, Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs, Int. J. Pharm., 507, 21, 10.1016\u002Fj.ijpharm.2016.04.071\nMuankaew, 2020, Self-assembly of cyclodextrin complexes: detection, obstacles and benefits, Pharmazie, 75, 307\nMunro, 2004, Safety assessment of γ-cyclodextrin, Regul. Toxicol. Pharmacol., 39, 3, 10.1016\u002Fj.yrtph.2004.05.008\nMura, 2020, Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: A review, Int. J. Pharm., 579, 10.1016\u002Fj.ijpharm.2020.119181\nOhira, 2015, Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema, Acta Ophthalmol., 93, 610, 10.1111\u002Faos.12803\nOhshita, 2021, Polypseudorotaxane-based supramolecular hydrogels consisting of cyclodextrins and Pluronics as stabilizing agents for antibody drugs, Carbohydr. Polym., 256, 10.1016\u002Fj.carbpol.2020.117419\nOhtani, 1989, Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes, Eur. J. Biochem., 186, 17, 10.1111\u002Fj.1432-1033.1989.tb15171.x\nParmar, 2018, Responsive cyclodextrins as polymeric carriers for drug delivery applications, 555\nPrajapati, 2022, Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery, J. Drug Deliv. Sci. Technol., 69\nPraphanwittaya, 2020, Aqueous solubility of kinase inhibitors: III the effect of acidic counter ion on the dovitinib\u002Fγ-cyclodextrin complexation, J. Incl. Phenom. Macrocycl. Chem., 98, 57, 10.1007\u002Fs10847-020-01009-7\nPraphanwittaya, 2020, Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization, J. Drug Deliv. Sci. Technol., 55\nPraphanwittaya, 2020, Aqueous solubility of kinase inhibitors: II the effect of hexadimethrine bromide on the dovitinib\u002Fγ-cyclodextrin complexation, J. Drug Deliv. Sci. Technol., 55\nPrinsen, M.K., 1990. Acute eye irritation\u002Fcorrosion study with gamma-cyclodextrin in albino rabbits. Unpublished report No. V90.405\u002F200069 from TNO-CIVO Institutes, Zeist, Netherlands. Submitted to WHO by Bioresco Ltd, Binningen, Switzerland.\nPrinsen, M.K., 1992. Sensitization study with gamma-CD in guinea pigs (maximization test). Unpublished report No. V92.575\u002F352063 from TNO-CIVO Institutes, Zeist, Netherlands. Submitted to WHO by Bioresco Ltd, Binningen, Switzerland.\nRaza, 2021, PLGA encapsulated γ-cyclodextrin-meropenem inclusion complex formulation for oral delivery, Int. J. Pharm., 597, 10.1016\u002Fj.ijpharm.2021.120280\nRodriguez-Perez, 2006, Drug solubilization and delivery from cyclodextrin-Pluronic aggregates, J. Nanosci. Nanotechnol., 6, 3179, 10.1166\u002Fjnn.2006.472\nSaarinen-Savolainen, 1998, Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line, Pharm. Res., 15, 1275, 10.1023\u002FA:1011956327987\nSaokham, 2020, Characterization and evaluation of ternary complexes of ascorbic acid with γ-cyclodextrin and poly(vinyl alcohol), Int. J. Mol. Sci., 21, 4399, 10.3390\u002Fijms21124399\nSaokham, 2017, γ-Cyclodextrin, Int. J. Pharm., 516, 278, 10.1016\u002Fj.ijpharm.2016.10.062\nSapino, 2007, Effect of akyl-γ-cyclodextrins on the stability of retinol, J. Incl. Phenom. Macrocycl. Chem., 57, 451, 10.1007\u002Fs10847-006-9233-8\nSchönbeck, 2019, Drug solubilization by mixtures of cyclodextrins: Additive and synergistic effects, Mol. Pharm., 16, 648, 10.1021\u002Facs.molpharmaceut.8b00953\nShityakov, 2017, Solubility profiles, hydration and desolvation of curcumin complexed with γ-cyclodextrin and hydroxypropyl-γ-cyclodextrin, J. Mol. Struct., 1134, 91, 10.1016\u002Fj.molstruc.2016.12.028\nShulman, 2015, Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study, Acta Ophthalmol., 93, 411, 10.1111\u002Faos.12744\nSivasubramanian, 2013, Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin, J. Nanosci. Nanotechnol., 13, 7271, 10.1166\u002Fjnn.2013.8091\nSoe, 2021, Effect of Soluplus® on γ-cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation, Pharm. Dev. Technol., 1\nŞoica, 2012, Betulin complex in γ-cyclodextrin derivatives: Properties and antineoplasic activities in in vitro and in vivo tumor models, Int. J. Mol. Sci., 13, 14992, 10.3390\u002Fijms131114992\nSripetch, 2020, Effect of porcine pancreatic α-amylase on dexamethasone release from aqueous solution containing natural γ-cyclodextrin, Int. J. Pharm., 585, 10.1016\u002Fj.ijpharm.2020.119452\nStella, 2008, Cyclodextrins, Toxicol. Pathol., 36, 30, 10.1177\u002F0192623307310945\nStella, 1999, Mechanisms of drug release from cyclodextrin complexes, Adv. Drug Deliv. Rev., 36, 3, 10.1016\u002FS0169-409X(98)00052-0\nSzejtil, 1988\nSzente, 2014, Supramolecular proteoglycan aggregate mimics: Cyclodextrin-assisted biodegradable polymer assemblies for electrostatic-driven drug delivery, Chem. Asian J., 9, 1365, 10.1002\u002Fasia.201301391\nSzente, 1998, Spontaneous opalescence of aqueous gamma-cyclodextrin solutions: complex formation or self-aggregation?, J. Pharm. Sci., 87, 778, 10.1021\u002Fjs9704341\nTanito, 2011, Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema, Invest. Ophthalmol. Vis. Sci., 52, 7944, 10.1167\u002Fiovs.11-8178\nTenjarla, 1998, Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery, J. Pharm. Sci., 87, 425, 10.1021\u002Fjs970361l\nTil, 1998, Subchronic (13-week) oral toxicity study of gamma-cyclodextrin in dogs, Regul. Toxicol. Pharmacol., 27, 159, 10.1006\u002Frtph.1998.1220\nTrotta, 2002, Investigation of haemolytic and complexation properties of γ-cyclodextrin carbonate derivatives, J. Incl. Phenom. Macrocycl. Chem., 44, 345, 10.1023\u002FA:1023013206635\nWang, 2012, A comparison investigation on the solubilization of betulin and betulinic acid in cyclodextrin derivatives, Nat. Prod. Commun., 7, 289\nWang, 2011, Solubilization of polycyclic aromatics in water by γ-cyclodextrin derivatives, Chem. Asian J., 6, 2390, 10.1002\u002Fasia.201100217\nWang, 2020, Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine, Int. J. Pharm., 584, 10.1016\u002Fj.ijpharm.2020.119391\nWei, 2021, Enrofloxacin\u002Fflorfenicol loaded cyclodextrin metal-organic-framework for drug delivery and controlled release, Drug Deliv., 28, 372, 10.1080\u002F10717544.2021.1879316\nXavier-Júnior, 2019, Elucidation of the mechanism of complexation between oncocalyxone A and cyclodextrins by isothermal titration calorimetry and molecular modeling, J. Mol. Liq., 274, 165, 10.1016\u002Fj.molliq.2018.10.129\nZhang, 2018, Enhanced stability of vitamin A palmitate microencapsulated by γ-cyclodextrin metal-organic frameworks, J. Microencapsul., 35, 249, 10.1080\u002F02652048.2018.1462417\nZhou, 2021, Latanoprost-loaded cyclodextrin microaggregate suspension eye drops for enhanced bioavailability and stability, Eur. J. Pharm. Sci., 160, 10.1016\u002Fj.ejps.2021.105758",{"VOID":857},"10.1016\u002Fj.ijpharm.2022.121654","2024-05-17T00:13:56.940+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517322002095",[861,878],{"id":862,"sortIndex":19,"researcher":18,"roles":863,"affiliations":864,"properties":873,"displayName":875,"givenName":18,"familyName":18},"0560fbd8-7c66-4d8a-a5ab-e08c55423f97",[99],[865],{"id":866,"sortIndex":19,"affiliation":867,"properties":18},"d7739f3c-80b1-4fd4-9bc7-dd515cf098ef",{"id":866,"createTime":18,"updateTime":18,"relativeEntities":868,"slug":18,"properties":869,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":872,"statistic":18},[],{"title":870},{"VI":871},"Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phyathai Road, Pathumwan, Bangkok 10330, Thailand",[],{"title":874,"gsAuthor":876},{"VI":875},"Phatsawee Jansook",{"VOID":877},"[\"KzoHAMAAAAAJ\"]",{"id":879,"sortIndex":114,"researcher":18,"roles":880,"affiliations":881,"properties":890,"displayName":892,"givenName":18,"familyName":18},"c799f668-39ef-4cf9-ac65-6bd70f5b87c2",[99],[882],{"id":883,"sortIndex":19,"affiliation":884,"properties":18},"27de0bd3-5857-4c9d-8a59-6783b0b14a10",{"id":883,"createTime":18,"updateTime":18,"relativeEntities":885,"slug":18,"properties":886,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":889,"statistic":18},[],{"title":887},{"VI":888},"Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland",[],{"title":891,"gsAuthor":893},{"VI":892},"Thorsteinn Loftsson",{"VOID":894},"[\"i_eYy2MAAAAJ\"]",{"url":859,"publisher":896,"properties":927},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":897,"slug":10,"properties":898,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":901,"manageAffiliations":906,"indexDatabases":912,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":899,"title":900},{"VOID":13},{"EN":15},[902],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":903,"label":904,"description":905,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[907],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":908,"slug":18,"properties":909,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":911,"statistic":18},[],{"title":910},{"EN":33},[],[913,920],{"id":37,"indexDatabase":914,"url":48,"indexYears":49,"academicFieldIds":919,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":915,"label":916,"description":917,"key":45,"publicationTags":918,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":921,"url":67,"indexYears":18,"academicFieldIds":926,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":922,"label":923,"description":924,"key":63,"publicationTags":925,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":928,"volume":930},{"VOID":929},"121654",{"VOID":931},"618",{"total":19,"publishYear":933,"statisticByYear":934},2022,{},"2022-04-01","2026-08-19T09:06:55.926+00:00",[65,52],{"id":939,"createTime":940,"updateTime":941,"relativeEntities":942,"slug":943,"properties":944,"entityType":88,"verifyStatus":89,"verifyTime":951,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":952,"fullTextUrl":18,"authors":953,"publicationType":182,"publisherRelationship":1010,"citationCount":1047,"citationInfo":1048,"publishDate":1051,"publishYear":1049,"citationAnalyzeStatus":353,"lastCitationAnalyze":1052,"indexDatabases":1053,"openAccess":18,"references":1054,"isForceReanalyzing":223},"c076c370-a93c-49fb-8017-2bcb058f32c2","2024-01-19T20:20:10.502+00:00","2026-08-17T18:12:00.759+00:00",[],"The-sustained-granulopoietic-effect-of-progenipoietin-encapsulated-in-multivesicular-liposomes",{"title":945,"gsPaper":947,"doi":949},{"EN":946},"The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes",{"VOID":948},"[\"8011889911412971439\"]",{"VOID":950},"10.1016\u002Fs0378-5173(03)00291-6","2024-04-28T02:28:32.029+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517303002916",[954,969,982,997],{"id":955,"sortIndex":19,"researcher":18,"roles":956,"affiliations":957,"properties":966,"displayName":968,"givenName":18,"familyName":18},"d4b432d5-0724-4dd5-a99e-03717c44a412",[99],[958],{"id":959,"sortIndex":19,"affiliation":960,"properties":18},"9cf2de80-70c5-4871-96f6-f052d5a930b2",{"id":959,"createTime":18,"updateTime":18,"relativeEntities":961,"slug":18,"properties":962,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":965,"statistic":18},[],{"title":963},{"VI":964},"SkyePharma Inc., 10450 Science Center Drive, San Diego, CA 92121, USA",[],{"title":967},{"VI":968},"Mysore P Ramprasad",{"id":970,"sortIndex":114,"researcher":18,"roles":971,"affiliations":972,"properties":979,"displayName":981,"givenName":18,"familyName":18},"2eaeaae1-4af2-4ec2-a6a1-b6c7dd4c6231",[99],[973],{"id":959,"sortIndex":19,"affiliation":974,"properties":18},{"id":959,"createTime":18,"updateTime":18,"relativeEntities":975,"slug":18,"properties":976,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":978,"statistic":18},[],{"title":977},{"VI":964},[],{"title":980},{"VI":981},"Arjang Amini",{"id":983,"sortIndex":128,"researcher":18,"roles":984,"affiliations":985,"properties":994,"displayName":996,"givenName":18,"familyName":18},"e47652e4-42da-4cbb-801a-b439e8f462ce",[99],[986],{"id":987,"sortIndex":19,"affiliation":988,"properties":18},"040db99e-4d44-44ea-b6f4-2732e032977f",{"id":987,"createTime":18,"updateTime":18,"relativeEntities":989,"slug":18,"properties":990,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":993,"statistic":18},[],{"title":991},{"VI":992},"Pharmacia Corporation, 4901 Searle Parkway, Skokie, IL 6007, USA",[],{"title":995},{"VI":996},"Tugrul Kararli",{"id":998,"sortIndex":142,"researcher":18,"roles":999,"affiliations":1000,"properties":1007,"displayName":1009,"givenName":18,"familyName":18},"d06b68d0-cc44-489e-883b-d82c410f1124",[99],[1001],{"id":959,"sortIndex":19,"affiliation":1002,"properties":18},{"id":959,"createTime":18,"updateTime":18,"relativeEntities":1003,"slug":18,"properties":1004,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1006,"statistic":18},[],{"title":1005},{"VI":964},[],{"title":1008},{"VI":1009},"Nandini V Katre",{"url":952,"publisher":1011,"properties":1042},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1012,"slug":10,"properties":1013,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1016,"manageAffiliations":1021,"indexDatabases":1027,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1014,"title":1015},{"VOID":13},{"EN":15},[1017],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1018,"label":1019,"description":1020,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1022],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1023,"slug":18,"properties":1024,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1026,"statistic":18},[],{"title":1025},{"EN":33},[],[1028,1035],{"id":37,"indexDatabase":1029,"url":48,"indexYears":49,"academicFieldIds":1034,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1030,"label":1031,"description":1032,"key":45,"publicationTags":1033,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1036,"url":67,"indexYears":18,"academicFieldIds":1041,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1037,"label":1038,"description":1039,"key":63,"publicationTags":1040,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1043,"volume":1045},{"VOID":1044},"93-103",{"VOID":1046},"261",30,{"total":1047,"publishYear":1049,"statisticByYear":1050},2003,{"2004":142,"2005":142,"2006":114,"2007":114,"2009":128,"2010":142,"2011":156,"2012":128,"2013":128,"2014":142,"2015":142,"2016":114,"2019":114,"2021":114},"2003-08-01","2026-08-17T18:12:00.758+00:00",[65,52],[1055,1063,1071,1079,1087,1090,1097,1100,1104,1108,1111,1117,1120,1126,1134,1140,1146,1152,1158,1162,1165,1172,1180,1188,1192,1196,1201,1205,1213,1217,1223,1226,1234],{"id":18,"text":1056,"url":1057,"identifiers":1058},"Bjorck, 2002, Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model, Int. J. Cancer, 100, 586, 10.1002\u002Fijc.10529","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.10529",{"mag":1059,"openalex":1060,"pm":1061,"doi":1062},"2046135281","W2046135281","12124809","10.1002\u002Fijc.10529",{"id":18,"text":1064,"url":1065,"identifiers":1066},"Blok, 1975, The effect of chain length and lipid phase transitions on the selective permeability properties of liposomes, Biochim. Biophys. Acta, 406, 187, 10.1016\u002F0005-2736(75)90003-6","https:\u002F\u002Fdoi.org\u002F10.1016\u002F0005-2736(75)90003-6",{"mag":1067,"openalex":1068,"pm":1069,"doi":1070},"2039388809","W2039388809","1191647","10.1016\u002F0005-2736(75)90003-6",{"id":18,"text":1072,"url":1073,"identifiers":1074},"Bowen, 1999, Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein, Exp. Hematol., 27, 425, 10.1016\u002FS0301-472X(98)00051-4","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0301-472x(98)00051-4",{"mag":1075,"openalex":1076,"pm":1077,"doi":1078},"2052829077","W2052829077","10089904","10.1016\u002Fs0301-472x(98)00051-4",{"id":18,"text":1080,"url":1081,"identifiers":1082},"de Haan, 2000, Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes, Br. J. Haematol., 110, 638, 10.1046\u002Fj.1365-2141.2000.02252.x","https:\u002F\u002Fdoi.org\u002F10.1046\u002Fj.1365-2141.2000.02252.x",{"mag":1083,"openalex":1084,"pm":1085,"doi":1086},"2132642180","W2132642180","10997976","10.1046\u002Fj.1365-2141.2000.02252.x",{"id":365,"text":1088,"url":367,"identifiers":1089},"Dempke, 2000, Human hematopoietic growth factors: old lessons and new perspectives, Anticancer Res., 20, 5155",{"doi":369},{"id":18,"text":1091,"url":1092,"identifiers":1093},"Ellena, 1999, Distribution of phospholipids and triglycerides in multivesicular lipid particles, Drug Deliv., 6, 97, 10.1080\u002F107175499267011","https:\u002F\u002Fdoi.org\u002F10.1080\u002F107175499267011",{"mag":1094,"openalex":1095,"doi":1096},"2158457155","W2158457155","10.1080\u002F107175499267011",{"id":18,"text":1098,"url":18,"identifiers":1099},"Finn, R.F., McGarity, K., Thurman, T., Nicastro, P., Walker, V., Klover, J., Hills, R., LaPorte, M., Vickery, L., Donovan, M., Klein, B., Siegel, N., 2001. Pegylated progenipoietin: synthesis and characterization. In: Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials. Abstract #6168.",{},{"id":18,"text":1101,"url":18,"identifiers":1102},"Fleming, 2001, Progenipoietin-1: a multifunctional agonist of the granulocyte colony-stimulating factor receptor and fetal liver tyrosine kinase-3 is a potent mobilizer of hematopoietic stem cells, Exp. Hematol., 29, 943, 10.1016\u002FS0301-472X(01)00675-0",{"doi":1103},"10.1016\u002FS0301-472X(01)00675-0",{"id":18,"text":1105,"url":18,"identifiers":1106},"Furuya, 1995, Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin’s lymphoma receiving chemotherapy, Int. J. Hematol., 61, 123, 10.1016\u002F0925-5710(95)00354-U",{"doi":1107},"10.1016\u002F0925-5710(95)00354-U",{"id":18,"text":1109,"url":18,"identifiers":1110},"Hills, R., Finn, R., Nicastro, P., Thurman, T., Thayer, K., Durham, W., Klover, J., Smith, W., Siegel, N., 2001. PEGylated leridistim: multiple approaches to lead selection. In: Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials. Abstract #6157.",{},{"id":1112,"text":1113,"url":1114,"identifiers":1115},"89792e28-0dc0-4a04-9859-150f00142bd2","Hollingshead, 1991, Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions, Drugs, 42, 300, 10.2165\u002F00003495-199142020-00009","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.2165\u002F00003495-199142020-00009",{"doi":1116},"10.2165\u002F00003495-199142020-00009",{"id":365,"text":1118,"url":367,"identifiers":1119},"Howell, 2001, Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology, Cancer J., 7, 219",{"doi":369},{"id":1121,"text":1122,"url":1123,"identifiers":1124},"e1530cd3-d550-4ea3-9a7d-2aa7fcb93bd4","Ishioka, 2001, Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function, Vaccine, 19, 3710, 10.1016\u002FS0264-410X(01)00102-5","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0264410X01001025",{"doi":1125},"10.1016\u002Fs0264-410x(01)00102-5",{"id":18,"text":1127,"url":1128,"identifiers":1129},"Katre, 1990, Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol, J. Immunol., 144, 209, 10.4049\u002Fjimmunol.144.1.209","https:\u002F\u002Fdoi.org\u002F10.4049\u002Fjimmunol.144.1.209",{"mag":1130,"openalex":1131,"pm":1132,"doi":1133},"1556748674","W1556748674","2295792","10.4049\u002Fjimmunol.144.1.209",{"id":1135,"text":1136,"url":1137,"identifiers":1138},"a0716483-2215-4f1f-856b-65ec792af042","Katre, 1993, The conjugation of proteins with polyethylene glycol and other polymers, Adv. Drug Deliv. Rev., 10, 91, 10.1016\u002F0169-409X(93)90005-O","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0169409X9390005O",{"doi":1139},"10.1016\u002F0169-409X(93)90005-O",{"id":1141,"text":1142,"url":1143,"identifiers":1144},"52fc3ed5-402b-480b-ada9-118c89ab1dbd","Katre, 1998, Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I), J. Pharm. Sci., 87, 1341, 10.1021\u002Fjs980080t","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0022354915506710",{"doi":1145},"10.1021\u002Fjs980080t",{"id":1147,"text":1148,"url":1149,"identifiers":1150},"dd4e853c-dd44-4e18-a4d4-de1e323f5ae3","Kim, 1983, Preparation of multivesicular liposomes, Biochim. Biophys. Acta, 728, 339, 10.1016\u002F0005-2736(83)90504-7","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0005273683905047",{"doi":1151},"10.1016\u002F0005-2736(83)90504-7",{"id":1153,"text":1154,"url":1155,"identifiers":1156},"2e52da9e-02c4-48a9-a976-234e5605d2d1","Langston, 2003, Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam), J. Control. Release, 89, 87, 10.1016\u002FS0168-3659(03)00073-7","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0168365903000737",{"doi":1157},"10.1016\u002Fs0168-3659(03)00073-7",{"id":18,"text":1159,"url":18,"identifiers":1160},"MacDonald, 2002, Donor pretreatment with progenipoietin-1 is superior to G-CSF in preventing Graft-versus-Host disease after allogeneic stem cell transplantation, Blood, 101, 2033, 10.1182\u002Fblood-2002-05-1529",{"doi":1161},"10.1182\u002Fblood-2002-05-1529",{"id":18,"text":1163,"url":18,"identifiers":1164},"MacVittie, 1998, Members of the progenipoietins, a family of chimeric FLT-3 ligand and G-CSF receptor agonists mobilize hematopoietic progenitor cells with different kinetics and efficiency in nonhuman primates, Blood, 92, 682a",{},{"id":18,"text":1166,"url":1167,"identifiers":1168},"Metcalf, 1992, Hemopoietic regulators, Trends Biochem. Sci., 17, 286, 10.1016\u002F0968-0004(92)90436-D","https:\u002F\u002Fdoi.org\u002F10.1016\u002F0968-0004(92)90436-d",{"openalex":1169,"pm":1170,"doi":1171},"W4253234117","1412701","10.1016\u002F0968-0004(92)90436-d",{"id":18,"text":1173,"url":1174,"identifiers":1175},"Molineux, 1997, Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential, Blood, 89, 3998, 10.1182\u002Fblood.V89.11.3998","https:\u002F\u002Fdoi.org\u002F10.1182\u002Fblood.v89.11.3998",{"mag":1176,"openalex":1177,"pm":1178,"doi":1179},"79123086","W79123086","9166838","10.1182\u002Fblood.v89.11.3998",{"id":18,"text":1181,"url":1182,"identifiers":1183},"Molineux, 1999, A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans, Exp. Hematol., 27, 1724, 10.1016\u002FS0301-472X(99)00112-5","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0301-472x(99)00112-5",{"mag":1184,"openalex":1185,"pm":1186,"doi":1187},"2033922294","W2033922294","10641590","10.1016\u002Fs0301-472x(99)00112-5",{"id":18,"text":1189,"url":18,"identifiers":1190},"Moore, 1991, Review: Stratton Lecture 1990. Clinical implications of positive and negative hematopoietic stem cell regulators, Blood, 78, 1, 10.1182\u002Fblood.V78.1.1.1",{"doi":1191},"10.1182\u002Fblood.V78.1.1.1",{"id":18,"text":1193,"url":18,"identifiers":1194},"Papayannopoulou, 1997, In vivo effects of Flt3\u002FFlk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor, Blood, 90, 620, 10.1182\u002Fblood.V90.2.620",{"doi":1195},"10.1182\u002Fblood.V90.2.620",{"id":18,"text":1197,"url":1198,"identifiers":1199},"Ramprasad, 2002, Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels, J. Control Release, 79, 207, 10.1016\u002FS0168-3659(01)00552-1","http:\u002F\u002Fdx.doi.org\u002F10.1016\u002Fs0168-3659(01)00552-1",{"doi":1200},"10.1016\u002Fs0168-3659(01)00552-1",{"id":18,"text":1202,"url":18,"identifiers":1203},"Streeter, 2001, Progenipoietins: biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor, Exp. Hematol., 29, 41, 10.1016\u002FS0301-472X(00)00616-0",{"doi":1204},"10.1016\u002FS0301-472X(00)00616-0",{"id":18,"text":1206,"url":1207,"identifiers":1208},"Sudo, 1997, Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice, Blood, 89, 3186, 10.1182\u002Fblood.V89.9.3186","https:\u002F\u002Fdoi.org\u002F10.1182\u002Fblood.v89.9.3186",{"mag":1209,"openalex":1210,"pm":1211,"doi":1212},"2236607890","W2236607890","9129021","10.1182\u002Fblood.v89.9.3186",{"id":18,"text":1214,"url":18,"identifiers":1215},"Veronese, 2001, Peptide and protein PEGylation: a review of problems and solutions, Biomaterials, 22, 405, 10.1016\u002FS0142-9612(00)00193-9",{"doi":1216},"10.1016\u002FS0142-9612(00)00193-9",{"id":1218,"text":1219,"url":1220,"identifiers":1221},"123a8262-02de-4e21-b366-63eca4a80a3a","Violand, 2002, Purification and characterization of progenipoietins produced in Escherichia coli, Protein Expr. Purif., 26, 275, 10.1016\u002FS1046-5928(02)00545-4","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1046592802005454",{"doi":1222},"10.1016\u002Fs1046-5928(02)00545-4",{"id":18,"text":1224,"url":18,"identifiers":1225},"Willis, R.C., 1999. Multivesicular liposomes utilizing neutral lipids to modify in vivo release. United States Patent #5962016.",{},{"id":18,"text":1227,"url":1228,"identifiers":1229},"Ye, 2000, DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs, J. Control. Release, 64, 155, 10.1016\u002FS0168-3659(99)00146-7","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0168-3659(99)00146-7",{"mag":1230,"openalex":1231,"pm":1232,"doi":1233},"2078093399","W2078093399","10640654","10.1016\u002Fs0168-3659(99)00146-7",{"id":1235,"text":1236,"url":1237,"identifiers":1238},"b8e81783-efec-4396-b53d-783d6e2beb63","Zeigler, 1994, Cellular and molecular characterization of the role of the flk-2\u002Fflt-3 receptor tyrosine kinase in hematopoietic stem cells, Blood, 84, 2422, 10.1182\u002Fblood.V84.8.2422.2422","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0006497120713583",{"doi":1239},"10.1182\u002Fblood.v84.8.2422.2422",{"id":1241,"createTime":1242,"updateTime":1243,"relativeEntities":1244,"slug":1245,"properties":1246,"entityType":88,"verifyStatus":89,"verifyTime":1255,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1256,"fullTextUrl":18,"authors":1257,"publicationType":182,"publisherRelationship":1327,"citationCount":1364,"citationInfo":1365,"publishDate":1368,"publishYear":1366,"citationAnalyzeStatus":353,"lastCitationAnalyze":1369,"indexDatabases":1370,"openAccess":18,"references":18,"isForceReanalyzing":223},"cf5390bd-e18a-46fa-8136-e5bea4b3ccb8","2024-02-08T11:43:21.676+00:00","2026-08-16T22:12:39.130+00:00",[],"Synthesis-and-in-vitro-evaluation-of-lipoamino-acid-and-carbohydrate-modified-enkephalins-as-potential-antinociceptive-agents",{"title":1247,"gsPaper":1249,"references":1251,"doi":1253},{"EN":1248},"Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents",{"VOID":1250},"[\"7451670927974508675\"]",{"VOID":1252},"Begley, 1996, The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system, J. Pharm. Pharmacol., 48, 136, 10.1111\u002Fj.2042-7158.1996.tb07112.x\nBrownson, 1994, Effect of peptidases at the blood–brain barrier on the permeability of enkephalin, J. Pharmacol. Exp. Ther., 270, 675\nBycroft, B.W., Chan, W.C., Chhabra, S.R., Hone, N.D., 1993. A novel lysine-protecting procedure for continuous flow solid phase synthesis of branched peptides. J. Chem. Soc. Chem. Commun. 778–779.\nDiMaio, 1982, Synthesis and pharmacological characterisation in vitro of cyclic enkephalin analogues: Effect of conformation constraints on opiate receptor selectivity, J. Med. Chem., 25, 1432, 10.1021\u002Fjm00354a008\nDrouillat, 1997, Solid phase synthesis of C-terminal carbohydrate modified enkephalins, Bioorg. Med. Chem. Lett., 7, 2247, 10.1016\u002FS0960-894X(97)00395-8\nFries, D.S., 1995. Analgesics. In: Foye, W.O., Lemke, T.L., Williams, D.A. (Eds.), Principles of Medicinal Chemistry. Williams and Wilkins, Philadelphia, pp. 247–269.\nGibbons, 1990, Lipidic peptides I. Synthesis, resolution and structure elucidation of lipidic amino acids and their homo- and hetero-oligomers, Liebigs Ann. Chem., 1990, 1175, 10.1002\u002Fjlac.1990199001215\nHorvat, 1993, Methionine-enkephalin related glycoconjugates, Int. J. Peptide Protein Res., 41, 399, 10.1111\u002Fj.1399-3011.1993.tb00456.x\nHughes, 1975, Identification of two related pentapeptides from the brain with potent opiate agonist activity, Nature, 258, 577, 10.1038\u002F258577a0\nMerrifield, 1963, Solid phase synthesis. I. The synthesis of a tetrapeptide, J. Am. Chem. Soc., 85, 2149, 10.1021\u002Fja00897a025\nMulder, 1992, Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception?, Trends Pharmacol. Sci., 13, 302, 10.1016\u002F0165-6147(92)90095-N\nPardridge, 1990, Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain-barrier, J. Pharmacol. Exp. Ther., 253, 884\nPardridge, 1996, Brain drug delivery and blood–brain barrier transport, Drug Deliv., 3, 99, 10.3109\u002F10717549609031180\nPolt, 1994, Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood–brain barrier, Proc. Natl. Acad. Sci. USA, 91, 7114, 10.1073\u002Fpnas.91.15.7114\nRink, 1987, Solid phase synthesis of protected peptide using a trialkoxy-diphenyl-methylester resin, Tetrahedron Lett., 28, 3787, 10.1016\u002FS0040-4039(00)96384-6\nTsuzuki, 1991, Adamantane as a brain-directed drug carrier for poorly absorbed drug: antinociceptive effects of [d-Ala2]Leu-enkephalin derivatives conjugated with the 1-adamantane moiety, Biochem. Pharmacol., 41, R5, 10.1016\u002F0006-2952(91)90616-D\nVarga-Defterdarovic, 1992, Glycoconjugates of opiod peptides, Int. J. Peptide Protein Res., 39, 12\nZlokovic, 1995, Cerebrovascular permeability to peptides: manipulations of transport systems at the blood–brain barrier, Pharm. Res., 12, 1395, 10.1023\u002FA:1016254514167",{"VOID":1254},"10.1016\u002Fs0378-5173(97)00328-1","2024-06-24T11:32:35.822+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517397003281",[1258,1273,1286,1299,1314],{"id":1259,"sortIndex":19,"researcher":18,"roles":1260,"affiliations":1261,"properties":1270,"displayName":1272,"givenName":18,"familyName":18},"07f9dc5e-217f-42ea-8a35-befc3338a1f8",[99],[1262],{"id":1263,"sortIndex":19,"affiliation":1264,"properties":18},"08576ed5-583c-4618-adab-f78bbf67ee29",{"id":1263,"createTime":18,"updateTime":18,"relativeEntities":1265,"slug":18,"properties":1266,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1269,"statistic":18},[],{"title":1267},{"VI":1268},"Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, 29–39 Brunswick Square, London WC1N 1AX, UK",[],{"title":1271},{"VI":1272},"Barrie Kellam",{"id":1274,"sortIndex":114,"researcher":18,"roles":1275,"affiliations":1276,"properties":1283,"displayName":1285,"givenName":18,"familyName":18},"4342381c-369e-4a82-876e-abbbc6ba5844",[99],[1277],{"id":1263,"sortIndex":19,"affiliation":1278,"properties":18},{"id":1263,"createTime":18,"updateTime":18,"relativeEntities":1279,"slug":18,"properties":1280,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1282,"statistic":18},[],{"title":1281},{"VI":1268},[],{"title":1284},{"VI":1285},"Bruno Drouillat",{"id":1287,"sortIndex":128,"researcher":18,"roles":1288,"affiliations":1289,"properties":1296,"displayName":1298,"givenName":18,"familyName":18},"8c8ef0e2-1f53-43af-a7bb-c5f4f32d0ffc",[99],[1290],{"id":1263,"sortIndex":19,"affiliation":1291,"properties":18},{"id":1263,"createTime":18,"updateTime":18,"relativeEntities":1292,"slug":18,"properties":1293,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1295,"statistic":18},[],{"title":1294},{"VI":1268},[],{"title":1297},{"VI":1298},"Gyula Dekany",{"id":1300,"sortIndex":142,"researcher":18,"roles":1301,"affiliations":1302,"properties":1311,"displayName":1313,"givenName":18,"familyName":18},"4534077a-da12-4412-be7a-9d3780031df6",[99],[1303],{"id":1304,"sortIndex":19,"affiliation":1305,"properties":18},"a25d9b5b-8eaa-4c4a-8102-e8c39742c513",{"id":1304,"createTime":18,"updateTime":18,"relativeEntities":1306,"slug":18,"properties":1307,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1310,"statistic":18},[],{"title":1308},{"VI":1309},"Department of Pharmacology, The School of Pharmacy, University of London, 29\u002F39 Brunswick Square, London WC1N 1AX, UK",[],{"title":1312},{"VI":1313},"Mike S Starr",{"id":1315,"sortIndex":156,"researcher":18,"roles":1316,"affiliations":1317,"properties":1324,"displayName":1326,"givenName":18,"familyName":18},"935bdd11-c4e9-42ad-a7f4-4fcdb9ba6e17",[99],[1318],{"id":1263,"sortIndex":19,"affiliation":1319,"properties":18},{"id":1263,"createTime":18,"updateTime":18,"relativeEntities":1320,"slug":18,"properties":1321,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1323,"statistic":18},[],{"title":1322},{"VI":1268},[],{"title":1325},{"VI":1326},"Istvan Toth",{"url":1256,"publisher":1328,"properties":1359},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1329,"slug":10,"properties":1330,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1333,"manageAffiliations":1338,"indexDatabases":1344,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1331,"title":1332},{"VOID":13},{"EN":15},[1334],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1335,"label":1336,"description":1337,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1339],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1340,"slug":18,"properties":1341,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1343,"statistic":18},[],{"title":1342},{"EN":33},[],[1345,1352],{"id":37,"indexDatabase":1346,"url":48,"indexYears":49,"academicFieldIds":1351,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1347,"label":1348,"description":1349,"key":45,"publicationTags":1350,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1353,"url":67,"indexYears":18,"academicFieldIds":1358,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1354,"label":1355,"description":1356,"key":63,"publicationTags":1357,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1360,"volume":1362},{"VOID":1361},"55-64",{"VOID":1363},"161",57,{"total":1364,"publishYear":1366,"statisticByYear":1367},1998,{"1999":156,"2000":351,"2001":128,"2002":142,"2004":114,"2005":156,"2006":142,"2007":142,"2008":351,"2009":142,"2011":142,"2012":350,"2013":156,"2014":156,"2015":142,"2022":114},"1998-02-01","2026-08-16T22:12:39.129+00:00",[65,52],{"id":1372,"createTime":1373,"updateTime":1374,"relativeEntities":1375,"slug":1376,"properties":1377,"entityType":88,"verifyStatus":89,"verifyTime":1386,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1387,"fullTextUrl":18,"authors":1388,"publicationType":182,"publisherRelationship":1456,"citationCount":19,"citationInfo":1493,"publishDate":1496,"publishYear":1494,"citationAnalyzeStatus":353,"lastCitationAnalyze":1374,"indexDatabases":1497,"openAccess":18,"references":18,"isForceReanalyzing":223},"40cad779-73c1-4b91-80e1-75bce9f6ad24","2023-12-17T19:29:33.091+00:00","2026-08-16T02:43:20.496+00:00",[],"Engineered-ionizable-lipid-nanoparticles-mediated-efficient-siRNA-delivery-to-macrophages-for-anti-inflammatory-treatment-of-acute-liver-injury",{"title":1378,"gsPaper":1380,"references":1382,"doi":1384},{"EN":1379},"Engineered ionizable lipid nanoparticles mediated efficient siRNA delivery to macrophages for anti-inflammatory treatment of acute liver injury",{"VOID":1381},"[\"16722823027740062357\"]",{"VOID":1383},"Abd Elwakil, 2019, Lung-endothelium-targeted nanoparticles based on a pH-sensitive lipid and the GALA peptide enable robust gene silencing and the regression of metastatic lung cancer, Adv. Funct. Mater., 29, 1807677, 10.1002\u002Fadfm.201807677\nAkinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat. Biotechnol., 26, 561, 10.1038\u002Fnbt1402\nBerg, R.D., Levitte, S., O Sullivan, M.P., O Leary, S.M., Cambier, C.J., Cameron, J., Takaki, K.K., Moens, C.B., Tobin, D.M., Keane, J., Ramakrishnan, L., 2016. Lysosomal Disorders Drive Susceptibility to Tuberculosis by Compromising Macrophage Migration. CELL 165, 139-152.\nCalvente, 2015, Specific hepatic delivery of procollagen a1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis, Hepatology, 62, 1285, 10.1002\u002Fhep.27936\nDahlman, 2014, In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight, Nat. Nanotechnol., 9, 648, 10.1038\u002Fnnano.2014.84\nDing, 2021, Boosting ionizable lipid nanoparticle-mediated in vivo mRNA delivery through optimization of lipid amine-head groups, Biomater. Sci., 9, 7534, 10.1039\u002FD1BM00866H\nDing, 2021, Identification of a potent ionizable lipid for efficient macrophage transfection and systemic anti-interleukin-1β siRNA delivery against acute liver failure, J. Mater. Chem. B, 9, 5136, 10.1039\u002FD1TB00736J\nDong, 2020, Transfection of hard-to-transfect primary human macrophages with Bax siRNA to reverse Resveratrol-induced apoptosis, RNA Biol., 17, 755, 10.1080\u002F15476286.2020.1730081\nDong, 2019, Strategies, design, and chemistry in siRNA delivery systems, ADV DRUG DELIVER REV, 144, 133, 10.1016\u002Fj.addr.2019.05.004\nDowdy, 2017, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol., 35, 222, 10.1038\u002Fnbt.3802\nDuchardt, 2007, A Comprehensive Model for the Cellular Uptake of Cationic Cell-penetrating Peptides, Traffic, 8, 848, 10.1111\u002Fj.1600-0854.2007.00572.x\nGanbold, 2018, Design of Mannose-Functionalized Curdlan Nanoparticles for Macrophage-Targeted siRNA Delivery, ACS Appl. Mater. Inter., 10, 14463, 10.1021\u002Facsami.8b02073\nGarber, 2018, Alnylam launches era of RNAi drugs, Nat. Biotechnol., 36, 777, 10.1038\u002Fnbt0918-777\nGe, 2020, Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury, Nano Lett., 20, 1738, 10.1021\u002Facs.nanolett.9b04957\nHajj, 2019, Branched-tail lipid nanoparticles potently deliver mRNA In vivo due to enhanced ionization at endosomal pH, Small, 15, 1805097, 10.1002\u002Fsmll.201805097\nHansel, 2010, The safety and side effects of monoclonal antibodies, Nat. Rev. Drug Discov., 9, 325, 10.1038\u002Fnrd3003\nHe, 2016, Suppression of hepatic inflammationvia systemic siRNA delivery by membrane-disruptive and endosomolytic helical polypeptide hybrid nanoparticles, ACS Nano, 10, 1859, 10.1021\u002Facsnano.5b05470\nHu, 2022, Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia, Sci. Adv., 8, 10.1126\u002Fsciadv.abm1418\nKanasty, 2013, Delivery materials for siRNA therapeutics, Nat. Mater., 12, 967, 10.1038\u002Fnmat3765\nKargaard, 2019, Polymeric siRNA gene delivery – transfection efficiency versus cytotoxicity, J. Control Release, 316, 263, 10.1016\u002Fj.jconrel.2019.10.046\nKauffman, 2015, Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs, Nano Lett., 15, 7300, 10.1021\u002Facs.nanolett.5b02497\nKelly, C., Yadav, A.B., Lawlor, C., Nolan, K., O Dwyer, J., Greene, C.M., McElvaney, N.G., Sivadas, N., Ramsey, J.M., Cryan, S., 2014. Therapeutic Aerosol Bioengineering of siRNA for the Treatment of Inflammatory Lung Disease by TNFα Gene Silencing in Macrophages. MOL PHARMACEUT 11, 4270-4279.\nKhalil, 2006, Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery, Pharmacol Rev, 58, 32, 10.1124\u002Fpr.58.1.8\nKulkarni, 2018, On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA, ACS Nano, 12, 4787, 10.1021\u002Facsnano.8b01516\nKulkarni, 2019, On the role of helper lipids in lipid nanoparticle formulations of siRNA, Nanoscale, 11, 21733, 10.1039\u002FC9NR09347H\nLiu, 2021, Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing, Nat. Mater., 20, 701, 10.1038\u002Fs41563-020-00886-0\nLiu, 2014, Macrophage polarization in inflammatory diseases, Int. J. Biol. Sci., 10, 520, 10.7150\u002Fijbs.8879\nLostalé-Seijo, 2018, Synthetic materials at the forefront of gene delivery, Nat. Rev. Chem., 2, 258, 10.1038\u002Fs41570-018-0039-1\nLove, K.T., Mahon, K.P., Levins, C.G., Whitehead, K.A., Querbes, W., Dorkin, J.R., Qin, J., Cantley, W., Qin, L.L., Racie, T., Frank-Kamenetsky, M., Yip, K.N., Alvarez, R., Sah, D.W.Y., de Fougerolles, A., Fitzgerald, K., Koteliansky, V., Akinc, A., Langer, R., Anderson, D.G., 2010. Lipid-like materials for low-dose, in vivo gene silencing. Proceedings of the National Academy of Sciences 107, 1864-1869.\nMurray, 2011, Protective and pathogenic functions of macrophage subsets, Nat. Rev. Immunol., 11, 723, 10.1038\u002Fnri3073\nPark, 2012, Protective effect of melittin on inflammation and apoptosis in acute liver failure, Apoptosis, 17, 61, 10.1007\u002Fs10495-011-0659-0\nQiu, 2021, Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient interleukin-12 cancer gene therapy, Adv. Mater., 33, 2006189, 10.1002\u002Fadma.202006189\nRejman, 2005, Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes, Mol. Ther., 12, 468, 10.1016\u002Fj.ymthe.2005.03.038\nRiley, 2021, Ionizable lipid nanoparticles for in utero mRNA delivery, Sci. Adv., 7, 10.1126\u002Fsciadv.aba1028\nSaunders, 2020, A nanoprimer to improve the systemic delivery of siRNA and mRNA, Nano Lett., 20, 4264, 10.1021\u002Facs.nanolett.0c00752\nSong, 2019, Lipidoid-siRNA nanoparticle-mediated IL-1β gene silencing for systemic arthritis therapy in a mouse model, Mol. Ther., 27, 1424, 10.1016\u002Fj.ymthe.2019.05.002\nTang, 2017, SiRNA crosslinked nanoparticles for the treatment of inflammation-induced liver injury, Adv. Sci., 4, 1600228, 10.1002\u002Fadvs.201600228\nWang, 2014, Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy, Angew. Chem. Int. Ed., 53, 2893, 10.1002\u002Fanie.201311245\nWang, 2014, Molecular mechanisms that influence the macrophage M1–M2 polarization balance, Front. Immunol., 5, 10.3389\u002Ffimmu.2014.00614\nWang, 2019, M2b macrophage polarization and its roles in diseases, J. Leukoc. Biol., 106, 345, 10.1002\u002FJLB.3RU1018-378RR\nWeng, 2019, RNAi therapeutic and its innovative biotechnological evolution, Biotechnol. Adv., 37, 801, 10.1016\u002Fj.biotechadv.2019.04.012\nWhitehead, 2009, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov., 8, 129, 10.1038\u002Fnrd2742\nWhitehead, 2011, Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery, Mol. Ther., 19, 1688, 10.1038\u002Fmt.2011.141\nWhitehead, 2014, Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity, Nat. Commun., 5, 1, 10.1038\u002Fncomms5277\nWu, 2019, Polymeric vector-mediated targeted delivery of anti-PAK1 siRNA to macrophages for efficient atherosclerosis treatment, ACS Biomater. Sci. Eng., 5, 4455, 10.1021\u002Facsbiomaterials.9b01076\nWynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038\u002Fnature12034\nYang, 2018, Theranostic Niosomes for Efficient siRNA\u002FMicroRNA Delivery and Activatable Near-Infrared Fluorescent Tracking of Stem Cells, ACS Appl. Mater. Inter., 10, 19494, 10.1021\u002Facsami.8b05513\nZhang, 2018, Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape, Nano Lett., 18, 6301, 10.1021\u002Facs.nanolett.8b02553",{"VOID":1385},"10.1016\u002Fj.ijpharm.2022.122489","2024-05-16T22:01:10.982+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517322010444",[1389,1404,1417,1430,1443],{"id":1390,"sortIndex":19,"researcher":18,"roles":1391,"affiliations":1392,"properties":1401,"displayName":1403,"givenName":18,"familyName":18},"9c01fc48-1121-4c37-9c97-69eabfd48e5b",[99],[1393],{"id":1394,"sortIndex":19,"affiliation":1395,"properties":18},"75015c18-de3c-4eee-a7b0-dab17b691a42",{"id":1394,"createTime":18,"updateTime":18,"relativeEntities":1396,"slug":18,"properties":1397,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1400,"statistic":18},[],{"title":1398},{"VI":1399},"Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, and School of Chemistry and Chemical Engineering, Shandong University, Jinan 25010, China",[],{"title":1402},{"VI":1403},"Hongqian Zhang",{"id":1405,"sortIndex":114,"researcher":18,"roles":1406,"affiliations":1407,"properties":1414,"displayName":1416,"givenName":18,"familyName":18},"3b8a429d-633e-4d4d-bd7f-422f3b032496",[99],[1408],{"id":1394,"sortIndex":19,"affiliation":1409,"properties":18},{"id":1394,"createTime":18,"updateTime":18,"relativeEntities":1410,"slug":18,"properties":1411,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1413,"statistic":18},[],{"title":1412},{"VI":1399},[],{"title":1415},{"VI":1416},"Feng Ding",{"id":1418,"sortIndex":128,"researcher":18,"roles":1419,"affiliations":1420,"properties":1427,"displayName":1429,"givenName":18,"familyName":18},"07d168af-bc09-45b1-baf9-4604380c5c70",[99],[1421],{"id":1394,"sortIndex":19,"affiliation":1422,"properties":18},{"id":1394,"createTime":18,"updateTime":18,"relativeEntities":1423,"slug":18,"properties":1424,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1426,"statistic":18},[],{"title":1425},{"VI":1399},[],{"title":1428},{"VI":1429},"Zongwei Zhu",{"id":1431,"sortIndex":142,"researcher":18,"roles":1432,"affiliations":1433,"properties":1440,"displayName":1442,"givenName":18,"familyName":18},"0dd987f3-51f2-4a2a-b4f7-d7d3ba44ceb7",[99],[1434],{"id":1394,"sortIndex":19,"affiliation":1435,"properties":18},{"id":1394,"createTime":18,"updateTime":18,"relativeEntities":1436,"slug":18,"properties":1437,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1439,"statistic":18},[],{"title":1438},{"VI":1399},[],{"title":1441},{"VI":1442},"Qian Sun",{"id":1444,"sortIndex":156,"researcher":18,"roles":1445,"affiliations":1446,"properties":1453,"displayName":1455,"givenName":18,"familyName":18},"11bc0acf-1fba-426f-8448-f1b2a42cb7d4",[99],[1447],{"id":1394,"sortIndex":19,"affiliation":1448,"properties":18},{"id":1394,"createTime":18,"updateTime":18,"relativeEntities":1449,"slug":18,"properties":1450,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1452,"statistic":18},[],{"title":1451},{"VI":1399},[],{"title":1454},{"VI":1455},"Chuanxu Yang",{"url":1387,"publisher":1457,"properties":1488},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1458,"slug":10,"properties":1459,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1462,"manageAffiliations":1467,"indexDatabases":1473,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1460,"title":1461},{"VOID":13},{"EN":15},[1463],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1464,"label":1465,"description":1466,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1468],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1469,"slug":18,"properties":1470,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1472,"statistic":18},[],{"title":1471},{"EN":33},[],[1474,1481],{"id":37,"indexDatabase":1475,"url":48,"indexYears":49,"academicFieldIds":1480,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1476,"label":1477,"description":1478,"key":45,"publicationTags":1479,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1482,"url":67,"indexYears":18,"academicFieldIds":1487,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1483,"label":1484,"description":1485,"key":63,"publicationTags":1486,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1489,"volume":1491},{"VOID":1490},"122489",{"VOID":1492},"631",{"total":19,"publishYear":1494,"statisticByYear":1495},2023,{},"2023-01-01",[65,52],{"id":1499,"createTime":1500,"updateTime":1501,"relativeEntities":1502,"slug":1503,"properties":1504,"entityType":88,"verifyStatus":89,"verifyTime":1511,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1512,"fullTextUrl":18,"authors":1513,"publicationType":182,"publisherRelationship":1529,"citationCount":1566,"citationInfo":1567,"publishDate":1570,"publishYear":1568,"citationAnalyzeStatus":353,"lastCitationAnalyze":1571,"indexDatabases":1572,"openAccess":18,"references":1573,"isForceReanalyzing":223},"45eb0a0a-8b1e-4767-805a-80dbf5ac9b69","2023-12-10T07:28:32.706+00:00","2026-08-14T23:41:28.885+00:00",[],"Determination-of-pKa-values-from-solubility-data",{"title":1505,"gsPaper":1507,"doi":1509},{"EN":1506},"Determination of pKa values from solubility data",{"VOID":1508},"[\"10175811404910820352\"]",{"VOID":1510},"10.1016\u002F0378-5173(82)90142-9","2024-05-02T21:24:22.201+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0378517382901429",[1514],{"id":1515,"sortIndex":19,"researcher":18,"roles":1516,"affiliations":1517,"properties":1526,"displayName":1528,"givenName":18,"familyName":18},"afe38255-fbb7-4583-a7bb-a9d425383d2a",[99],[1518],{"id":1519,"sortIndex":19,"affiliation":1520,"properties":18},"0955b685-3330-4536-9236-3a740fc66360",{"id":1519,"createTime":18,"updateTime":18,"relativeEntities":1521,"slug":18,"properties":1522,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1525,"statistic":18},[],{"title":1523},{"VI":1524},"Schering AG, D. Galenik, Postfach 65 03 11, D-1000 Berlin 65 F.R.G.",[],{"title":1527},{"VI":1528},"Ingfried Zimmermann",{"url":1512,"publisher":1530,"properties":1561},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1531,"slug":10,"properties":1532,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1535,"manageAffiliations":1540,"indexDatabases":1546,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1533,"title":1534},{"VOID":13},{"EN":15},[1536],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1537,"label":1538,"description":1539,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1541],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1542,"slug":18,"properties":1543,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1545,"statistic":18},[],{"title":1544},{"EN":33},[],[1547,1554],{"id":37,"indexDatabase":1548,"url":48,"indexYears":49,"academicFieldIds":1553,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1549,"label":1550,"description":1551,"key":45,"publicationTags":1552,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1555,"url":67,"indexYears":18,"academicFieldIds":1560,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1556,"label":1557,"description":1558,"key":63,"publicationTags":1559,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1562,"volume":1564},{"VOID":1563},"57-65",{"VOID":1565},"13",39,{"total":1566,"publishYear":1568,"statisticByYear":1569},1982,{"1984":114,"1986":128,"1988":128,"1989":128,"1990":128,"1994":128,"2001":114,"2002":114,"2004":114,"2005":114,"2007":114,"2010":114,"2013":114,"2015":114,"2016":156,"2018":128,"2019":114,"2022":114,"2024":128,"2025":128},"1982-12-01","2026-08-14T23:41:28.884+00:00",[65,52],[1574,1577,1580,1583],{"id":18,"text":1575,"url":18,"identifiers":1576},"Albert, 1971",{},{"id":18,"text":1578,"url":18,"identifiers":1579},"Draper, 1981",{},{"id":18,"text":1581,"url":18,"identifiers":1582},"Dunn, 1974",{},{"id":1584,"text":1585,"url":1586,"identifiers":1587},"d6ac2e34-20e6-4ec7-a881-02e5273e2076","Krebs, 1945, Dissociation constant, solubility and the pH value of the solvent, J. Chem. Soc., 593, 10.1039\u002Fjr9450000593","https:\u002F\u002Fxlink.rsc.org\u002F?DOI=jr9450000593",{"doi":1588},"10.1039\u002Fjr9450000593",{"id":1590,"createTime":1591,"updateTime":1592,"relativeEntities":1593,"slug":1594,"properties":1595,"entityType":88,"verifyStatus":89,"verifyTime":1604,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1605,"fullTextUrl":18,"authors":1606,"publicationType":182,"publisherRelationship":1729,"citationCount":19,"citationInfo":1766,"publishDate":1769,"publishYear":1767,"citationAnalyzeStatus":353,"lastCitationAnalyze":1592,"indexDatabases":1770,"openAccess":18,"references":18,"isForceReanalyzing":223},"dd0a9e50-c482-47b9-8142-287e58a44aa2","2024-02-09T11:44:26.982+00:00","2026-08-14T08:20:32.799+00:00",[],"Study-of-amphotericin-B-magnetic-liposomes-for-brain-targeting",{"title":1596,"gsPaper":1598,"references":1600,"doi":1602},{"EN":1597},"Study of amphotericin B magnetic liposomes for brain targeting",{"VOID":1599},"[\"7848007772996620792\"]",{"VOID":1601},"Adler-Moore, 2008, Amphotericin B lipid preparations: what are the differences?, Clin. Microbiol. Infect., 14, 25, 10.1111\u002Fj.1469-0691.2008.01979.x\nAlexiou, 2000, Locoregional cancer treatment with magnetic drug targeting, Cancer Res., 60, 6641\nBenyettou, 2009, Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate, Int. J. Pharm., 379, 324, 10.1016\u002Fj.ijpharm.2009.04.010\nBianchi, 2012, Magnetic solid-phase extraction based on diphenyl functionalization of Fe3O4 magnetic nanoparticles for the determination of polycyclic aromatic hydrocarbons in urine samples, J. Chromatogr. A, 1231, 8, 10.1016\u002Fj.chroma.2012.02.015\nBlasi, 2013, Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity, Int. J. Pharm., 454, 316, 10.1016\u002Fj.ijpharm.2013.06.037\nCherry, 2013, A comprehensive model of magnetic particle motion during magnetic drug targeting, Int. J. Multiphase Flow, 59, 173, 10.1016\u002Fj.ijmultiphaseflow.2013.11.007\nChertok, 2008, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials, 29, 487, 10.1016\u002Fj.biomaterials.2007.08.050\nChertok, 2010, Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration, Biomaterials, 31, 6317, 10.1016\u002Fj.biomaterials.2010.04.043\nDiPietro, 2010, Determining magnetic nanoparticle size distributions from thermomagnetic measurements, Appl. Phys. Lett., 96, 222506, 10.1063\u002F1.3441411\nDoolittle, 2000, Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors, Cancer, 88, 637, 10.1002\u002F(SICI)1097-0142(20000201)88:3\u003C637::AID-CNCR22>3.0.CO;2-Y\nEckman, 1974, A critical evaluation of the principles governing the advantages of intra-arterial infusions, J. Pharmacokinet. Biopharm., 2, 257, 10.1007\u002FBF01059765\nEl-Samaligy, 2006, Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation, Int. J. Pharm., 308, 140, 10.1016\u002Fj.ijpharm.2005.11.006\nEllis, 2002, Amphotericin B: spectrum and resistance, J. Antimicrob. Chemother., 49, 7, 10.1093\u002Fjac\u002F49.suppl_1.7\nGao, 2014, In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide, Int. J. Pharm., 466, 8, 10.1016\u002Fj.ijpharm.2014.03.012\nGroll, 1998, Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development, Adv. Pharmacol., 44, 343, 10.1016\u002FS1054-3589(08)60129-5\nHaeri, 2013, Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes, Int. J. Pharm., 455, 320, 10.1016\u002Fj.ijpharm.2013.07.003\nIman, 2011, Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B, Int. J. Pharm., 408, 163, 10.1016\u002Fj.ijpharm.2011.01.044\nJoshi, 2007, Intra-arterial drug delivery: a concise review, J. Neurosurg. Anesthesiol., 19, 111, 10.1097\u002FANA.0b013e318033da41\nKim, 2009, The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator, Biomaterials, 30, 5751, 10.1016\u002Fj.biomaterials.2009.07.021\nKong, 2012, Magnetic targeting of nanoparticles across the intact blood–brain barrier, J. Control. Release, 164, 49, 10.1016\u002Fj.jconrel.2012.09.021\nLiu, 1992, Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes, Biochim. Biophys. Acta (BBA) Biomembr., 1104, 95, 10.1016\u002F0005-2736(92)90136-A\nMedeiros, 2011, Stimuli-responsive magnetic particles for biomedical applications, Int. J. Pharm., 403, 139, 10.1016\u002Fj.ijpharm.2010.10.011\nMessori, 2013, Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis, Clin. Infect. Dis., 57, 1783, 10.1093\u002Fcid\u002Fcit588\nNahar, 2014, Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature, Int. J. Pharm., 464, 185, 10.1016\u002Fj.ijpharm.2014.01.007\nPradhan, 2007, Preparation and characterization of manganese ferrite-based magnetic liposomes for hyperthermia treatment of cancer, J. Magn. Magn. Mater., 311, 208, 10.1016\u002Fj.jmmm.2006.10.1179\nPradhan, 2010, Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy, J. Control. Release, 142, 108, 10.1016\u002Fj.jconrel.2009.10.002\nSerrano, 2013, Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations, Int. J. Pharm., 447, 38, 10.1016\u002Fj.ijpharm.2013.02.038\nShubayev, 2009, Magnetic nanoparticles for theragnostics, Adv. Drug Deliv. Rev., 61, 467, 10.1016\u002Fj.addr.2009.03.007\nSu, 2012, PEG\u002FRGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting, Int. J. Pharm., 426, 170, 10.1016\u002Fj.ijpharm.2012.01.013\nSundaresan, 2014, Dual-responsive polymer-coated iron oxide nanoparticles for drug delivery and imaging applications, Int. J. Pharm., 466, 1, 10.1016\u002Fj.ijpharm.2014.03.016\nTorrado, 2008, Amphotericin B formulations and drug targeting, J. Pharm. Sci., 97, 2405, 10.1002\u002Fjps.21179\nVan de Ven, 2012, PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to fungizone and AmBisome, J. Control. Release, 161, 795, 10.1016\u002Fj.jconrel.2012.05.037\nZhang, 2008, Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038\u002Fsj.clpt.6100400\nZhao, 2008, Synthesis of cross-linked magnetic composite microspheres containing carboxyl groups, Front. Chem. China, 3, 81, 10.1007\u002Fs11458-008-0012-5",{"VOID":1603},"10.1016\u002Fj.ijpharm.2014.08.035","2024-06-26T20:57:50.876+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0378517314006012",[1607,1622,1637,1652,1668,1681,1694,1707],{"id":1608,"sortIndex":19,"researcher":18,"roles":1609,"affiliations":1610,"properties":1619,"displayName":1621,"givenName":18,"familyName":18},"ca3d3776-97a6-4774-9969-92158dfa0a14",[99],[1611],{"id":1612,"sortIndex":19,"affiliation":1613,"properties":18},"dd71e3de-6b79-4127-820c-ad04bf2aa242",{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1614,"slug":18,"properties":1615,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1618,"statistic":18},[],{"title":1616},{"VI":1617},"Department of Pharmacy, Hebei University of Science and Technology, Yuhua East Road 70, Shijiazhuang 050018, PR China",[],{"title":1620},{"VI":1621},"Mengyu Zhao",{"id":1623,"sortIndex":114,"researcher":18,"roles":1624,"affiliations":1625,"properties":1634,"displayName":1636,"givenName":18,"familyName":18},"03d79e79-0130-48bf-ba75-931a7de76523",[99],[1626],{"id":1627,"sortIndex":19,"affiliation":1628,"properties":18},"47c787a0-ac1b-4ec5-859e-62aaeb5bf941",{"id":1627,"createTime":18,"updateTime":18,"relativeEntities":1629,"slug":18,"properties":1630,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1633,"statistic":18},[],{"title":1631},{"VI":1632},"Department of Immunology, Hebei Medical University, Zhongshan East Road 361, Shijiazhuang 050017, PR China",[],{"title":1635},{"VI":1636},"Jie Hu",{"id":1638,"sortIndex":128,"researcher":18,"roles":1639,"affiliations":1640,"properties":1647,"displayName":1649,"givenName":18,"familyName":18},"1c374d38-c037-4049-989e-512281c5f1e4",[99],[1641],{"id":1612,"sortIndex":19,"affiliation":1642,"properties":18},{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1643,"slug":18,"properties":1644,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1646,"statistic":18},[],{"title":1645},{"VI":1617},[],{"title":1648,"gsAuthor":1650},{"VI":1649},"Linan Zhang",{"VOID":1651},"[\"WQuLq0MAAAAJ\"]",{"id":1653,"sortIndex":142,"researcher":18,"roles":1654,"affiliations":1655,"properties":1664,"displayName":1666,"givenName":18,"familyName":18},"11c554a0-7d75-4df0-aceb-f8934712aef5",[99],[1656],{"id":1657,"sortIndex":19,"affiliation":1658,"properties":18},"932066f8-2071-4c64-a94c-3f4edc0e34da",{"id":1657,"createTime":18,"updateTime":18,"relativeEntities":1659,"slug":18,"properties":1660,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1663,"statistic":18},[],{"title":1661},{"VI":1662},"Department of Pharmaceutics, New Drug Research and Development Center, North China Pharmaceutical Group Corporation, Heping East Road 388, Shijiazhuang 050015, PR China",[],{"title":1665,"gsAuthor":1667},{"VI":1666},"Li Zhang",{"VOID":1651},{"id":1669,"sortIndex":156,"researcher":18,"roles":1670,"affiliations":1671,"properties":1678,"displayName":1680,"givenName":18,"familyName":18},"6730133a-1d60-472b-b241-4e7e7d330063",[99],[1672],{"id":1612,"sortIndex":19,"affiliation":1673,"properties":18},{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1674,"slug":18,"properties":1675,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1677,"statistic":18},[],{"title":1676},{"VI":1617},[],{"title":1679},{"VI":1680},"Yongjun Sun",{"id":1682,"sortIndex":170,"researcher":18,"roles":1683,"affiliations":1684,"properties":1691,"displayName":1693,"givenName":18,"familyName":18},"b12473f5-7c9b-40e1-a647-bcafb8709046",[99],[1685],{"id":1612,"sortIndex":19,"affiliation":1686,"properties":18},{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1687,"slug":18,"properties":1688,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1690,"statistic":18},[],{"title":1689},{"VI":1617},[],{"title":1692},{"VI":1693},"Nan Ma",{"id":1695,"sortIndex":351,"researcher":18,"roles":1696,"affiliations":1697,"properties":1704,"displayName":1706,"givenName":18,"familyName":18},"d40ac8a6-68b4-4e6a-842f-7fd0bc80dcc8",[99],[1698],{"id":1612,"sortIndex":19,"affiliation":1699,"properties":18},{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1700,"slug":18,"properties":1701,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1703,"statistic":18},[],{"title":1702},{"VI":1617},[],{"title":1705},{"VI":1706},"Xiaolong Chen",{"id":1708,"sortIndex":350,"researcher":18,"roles":1709,"affiliations":1710,"properties":1726,"displayName":1728,"givenName":18,"familyName":18},"88774049-0d97-4e8d-91ca-3af365ccb6b3",[99],[1711,1717],{"id":1612,"sortIndex":19,"affiliation":1712,"properties":18},{"id":1612,"createTime":18,"updateTime":18,"relativeEntities":1713,"slug":18,"properties":1714,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1716,"statistic":18},[],{"title":1715},{"VI":1617},[],{"id":1718,"sortIndex":114,"affiliation":1719,"properties":1725},"6285dfd3-0223-4f2a-b9de-6c5a0fea75fe",{"id":1718,"createTime":18,"updateTime":18,"relativeEntities":1720,"slug":18,"properties":1721,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1724,"statistic":18},[],{"title":1722},{"VI":1723},"State Key Laboratory Breeding Base—Hebei Province Key Laboratory of Molecular Chemistry for Drug, PR China",[],{},{"title":1727},{"VI":1728},"Zibin Gao",{"url":1605,"publisher":1730,"properties":1761},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1731,"slug":10,"properties":1732,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1735,"manageAffiliations":1740,"indexDatabases":1746,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1733,"title":1734},{"VOID":13},{"EN":15},[1736],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1737,"label":1738,"description":1739,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1741],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1742,"slug":18,"properties":1743,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1745,"statistic":18},[],{"title":1744},{"EN":33},[],[1747,1754],{"id":37,"indexDatabase":1748,"url":48,"indexYears":49,"academicFieldIds":1753,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1749,"label":1750,"description":1751,"key":45,"publicationTags":1752,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1755,"url":67,"indexYears":18,"academicFieldIds":1760,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1756,"label":1757,"description":1758,"key":63,"publicationTags":1759,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1762,"volume":1764},{"VOID":1763},"9-16",{"VOID":1765},"475",{"total":19,"publishYear":1767,"statisticByYear":1768},2014,{},"2014-11-01",[65,52],{"id":1772,"createTime":1773,"updateTime":1774,"relativeEntities":1775,"slug":1776,"properties":1777,"entityType":88,"verifyStatus":89,"verifyTime":1786,"verifyNote":91,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1787,"fullTextUrl":18,"authors":1788,"publicationType":182,"publisherRelationship":1845,"citationCount":1882,"citationInfo":1883,"publishDate":1886,"publishYear":1884,"citationAnalyzeStatus":353,"lastCitationAnalyze":1887,"indexDatabases":1888,"openAccess":18,"references":18,"isForceReanalyzing":223},"f6de2fae-eb48-4589-80e2-55fb22713d3c","2024-01-01T16:07:40.400+00:00","2026-08-14T06:40:52.921+00:00",[],"Enhanced-delivery-of-mitomycin-C-prodrugs-through-the-skin",{"title":1778,"gsPaper":1780,"references":1782,"doi":1784},{"EN":1779},"Enhanced delivery of mitomycin C prodrugs through the skin",{"VOID":1781},"[\"3221348097845492827\"]",{"VOID":1783},"Fox, 1979, General physical model for simultaneous diffusion and metabolism in biological membranes. The computational approach for the steady-state case, Int. J. Pharm., 2, 41, 10.1016\u002F0378-5173(79)90027-9\nGeran, 1972, Protocols for screening chemical agents and natural products against animal tumors and other biological systems, Cancer Chemother. Rep., 3, 1\nHiguchi, 1960, Physical chemical analysis of percutaneous absorption process from creams and ointments, J. Soc. Cosmet. Chem., 11, 85\nHiguchi, 1978, Design of chemical structure for optimal dermal delivery, Vol. 7, 121\nIdson, 1975, Percutaneous absorption, J. Pharm. Sci., 64, 901, 10.1002\u002Fjps.2600640604\nKojima, 1978, Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate, Chem., Pharm. Bull., 26, 1818, 10.1248\u002Fcpb.26.1818\nKojima, 1980, Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C, J. Pharm. Pharmacol., 32, 30, 10.1111\u002Fj.2042-7158.1980.tb12840.x\nLoftsson, 1981, Improved delivery through biological membranes X. Percutaneous absorption and metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs, J. Pharm. Sci., 70, 756, 10.1002\u002Fjps.2600700710\nMøllgaard, 1982, Pro-drugs as drug delivery systems XXIII Improved dermal delivery of 5-fluorouracil through human skin via N-acyloxymethyl pro-drug derivatives, Int. J. Pharm., 12, 153, 10.1016\u002F0378-5173(82)90115-6\nRoos, 1984, Physicochemical and antitumor characteristics of some polyamino acid prodrugs of mitomycin C, Int. J. Pharm., 22, 75, 10.1016\u002F0378-5173(84)90047-4\nSasaki, 1983, Development of lipophilic prodrugs of mitomycin C III. Physicochemical and biological properties of newly synthesized alkoxycarbonyl derivatives, Chem. Pharm. Bull., 31, 4083, 10.1248\u002Fcpb.31.4083\nSasaki, 1983, Development of lipophilic prodrugs of mitomycin C. I. Synthesis and antitumor activity of 1a-N-substituted derivatives with aromatic pro-moiety, Int. J. Pharm., 15, 49, 10.1016\u002F0378-5173(83)90066-2\nSasaki, 1983, Development of lipophilic prodrugs of mitomycin C. II. Stability and bioactivation of 1a-N-substituted derivatives with aromatic pro-moiety, Int. J. Pharm., 15, 61, 10.1016\u002F0378-5173(83)90067-4\nSloan, 1983, Prodrugs of 6-thiopurines: enhanced delivery through the skin, J. Pharm. Sci., 72, 372, 10.1002\u002Fjps.2600720413\nTakakura, 1984, Enhanced lymphatic delivery of mitomycin C conjugated with dextran, Cancer Res., 44, 2505\nYu, 1979, Physical model evaluation of topical prodrug delivery — simultaneous transport and bioconversion of vidarabine-5'-valerate. I. Physical model development, J. Pharm. Sci., 68, 1341, 10.1002\u002Fjps.2600681104",{"VOID":1785},"10.1016\u002F0378-5173(85)90107-3","2024-05-16T20:41:57.789+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0378517385901073",[1789,1804,1817,1832],{"id":1790,"sortIndex":19,"researcher":18,"roles":1791,"affiliations":1792,"properties":1801,"displayName":1803,"givenName":18,"familyName":18},"ab8966e3-8947-4fd3-b1f0-3b112d42e1b5",[99],[1793],{"id":1794,"sortIndex":19,"affiliation":1795,"properties":18},"15898812-107e-41e0-9e0d-4514a983b410",{"id":1794,"createTime":18,"updateTime":18,"relativeEntities":1796,"slug":18,"properties":1797,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1800,"statistic":18},[],{"title":1798},{"VI":1799},"Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606, Japan",[],{"title":1802},{"VI":1803},"Mukai Eiji",{"id":1805,"sortIndex":114,"researcher":18,"roles":1806,"affiliations":1807,"properties":1814,"displayName":1816,"givenName":18,"familyName":18},"4d1fde06-cff3-4a0b-b46b-a265659f46a4",[99],[1808],{"id":1794,"sortIndex":19,"affiliation":1809,"properties":18},{"id":1794,"createTime":18,"updateTime":18,"relativeEntities":1810,"slug":18,"properties":1811,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1813,"statistic":18},[],{"title":1812},{"VI":1799},[],{"title":1815},{"VI":1816},"Arase Keiko",{"id":1818,"sortIndex":128,"researcher":18,"roles":1819,"affiliations":1820,"properties":1827,"displayName":1829,"givenName":18,"familyName":18},"dc5be955-7e2b-40a8-93fb-c3c94af8f559",[99],[1821],{"id":1794,"sortIndex":19,"affiliation":1822,"properties":18},{"id":1794,"createTime":18,"updateTime":18,"relativeEntities":1823,"slug":18,"properties":1824,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1826,"statistic":18},[],{"title":1825},{"VI":1799},[],{"title":1828,"gsAuthor":1830},{"VI":1829},"Hashida Mitsuru",{"VOID":1831},"[\"DQhsmkQAAAAJ\"]",{"id":1833,"sortIndex":142,"researcher":18,"roles":1834,"affiliations":1835,"properties":1842,"displayName":1844,"givenName":18,"familyName":18},"6dfb7c5a-4ad9-4ee3-acd4-53886835e719",[99],[1836],{"id":1794,"sortIndex":19,"affiliation":1837,"properties":18},{"id":1794,"createTime":18,"updateTime":18,"relativeEntities":1838,"slug":18,"properties":1839,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1841,"statistic":18},[],{"title":1840},{"VI":1799},[],{"title":1843},{"VI":1844},"Sezaki Hitoshi",{"url":1787,"publisher":1846,"properties":1877},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1847,"slug":10,"properties":1848,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1851,"manageAffiliations":1856,"indexDatabases":1862,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1849,"title":1850},{"VOID":13},{"EN":15},[1852],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1853,"label":1854,"description":1855,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},[1857],{"id":29,"createTime":18,"updateTime":18,"relativeEntities":1858,"slug":18,"properties":1859,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1861,"statistic":18},[],{"title":1860},{"EN":33},[],[1863,1870],{"id":37,"indexDatabase":1864,"url":48,"indexYears":49,"academicFieldIds":1869,"indexDatabaseRanking":52},{"id":39,"createTime":18,"updateTime":18,"relativeEntities":1865,"label":1866,"description":1867,"key":45,"publicationTags":1868,"standard":18},[],{"EN":42,"VI":42},{"EN":42,"VI":44},[47],[51],{"id":54,"indexDatabase":1871,"url":67,"indexYears":18,"academicFieldIds":1876,"indexDatabaseRanking":18},{"id":56,"createTime":18,"updateTime":18,"relativeEntities":1872,"label":1873,"description":1874,"key":63,"publicationTags":1875,"standard":18},[],{"EN":59,"VI":59},{"EN":61,"VI":62},[65,66],[69],{"pages":1878,"volume":1880},{"VOID":1879},"95-103",{"VOID":1881},"25",33,{"total":1882,"publishYear":1884,"statisticByYear":1885},1985,{"1986":128,"1987":350,"1988":128,"1989":114,"1990":128,"1993":128,"1995":114,"1996":114,"1997":114,"1999":114,"2000":114,"2001":114,"2003":142,"2004":128,"2005":114,"2006":114,"2008":128,"2016":114,"2018":114},"1985-06-01","2026-08-14T06:40:52.920+00:00",[65,52]]